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Introduction
Classification
Over the past three decades, several classification schemes have been used for the non-
Hodgkin’s lymphomas (NHL). First, the Rappaport classification described lymphomas by their
architecture and morphology. Subsequently there were the Lukes-Collins and Kiel classifica-
tions and the Working Formulation, recognising the B and T-lymphocyte origin and the
differentiation of the neoplastic cells in the lymphomas. Later, the Revised European American
Classification of Lymphoid Neoplasms (REAL) was developed [1], gathering lymphomas and
lymphoid leukaemias and paying attention to morphology, immunologic studies, cytogenetics
and the clinical behaviour. This classification has been updated and revised into the current
World Health Organization (WHO) classification [2]. Here, neoplasms are stratified according
to their lineage (e.g. myeloid, lymphoid); furthermore, within each category distinct diseases
are defined according to morphology, immunophenotype, genetic features and clinical charac-
teristics.
Indolent lymphomas represent 35-40% of the non-Hodgkin’s lymphomas in the Western
countries. The most common subtype is the follicular lymphoma, which will be discussed in this
thesis.
Morphology, grading and immunophenotype
Follicular lymphoma is a tumour of follicle center cells of lymph nodes, usually a mixture of
centrocytes (cleaved follicle center cells, ‘small cells’) and centroblasts (large non-cleaved follicle
center cells, ‘large cells’). Centrocytes typically predominate. The proportion of centroblasts
varies, and the clinical aggressiveness of the tumour increases with increasing numbers of
centroblasts.
Follicular lymphoma originates from follicle center B-cells, usually demonstrating surface
immunoglobulin. Almost all cases express HLA-DR and pan B-cell antigens (CD19, CD20,
CD79a), CD21, and CD10, but lack CD5, CD43 and CD11c. Cytoplasmic staining for bcl-2
protein is strongly positive, in contrast to normal germinal center B-cells.
Cytogenetics
Approximately 85% of follicular lymphomas have the t(14;18) translocation [3]. Here, the
proto-oncogene bcl-2, located on chromosome 18, is juxtaposed to the transciptionally active
immunoglobulin heavy chain gene on chromosome 14, forming the bcl-2/IgH rearrangement
and increasing the expression of bcl-2. This leads to inhibition of programmed cell death
(apoptosis) [4]. Overexpression of bcl-2 is the first step towards malignant transformation,
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which requires additional hits. This is also suggested by reports of t(14;18) positive B-cells in
blood and organ samples of healthy individuals [5-7]. Dedifferentiation of follicular lymphoma
into a lymphoma of a higher malignancy grade occurs frequently.
Disease associated chromosomal markers, like the t(14;18), facilitate detection of malig-
nant cells in patient samples. With the sensitive polymerase chain reaction one abnormal cell
with the aberrant DNA can be detected in a background of about 105 to 106 normal cells. After
using qualitative [8] and semi-quantitative assays [9,10], now the real-time quantitative PCR
[11] has emerged in molecular diagnostics for monitoring disease activity.
Clinical characteristics
Follicular lymphoma most frequently presents in middle-aged and elderly individuals, with a
median age at diagnosis of 55-65 years. Most patients present with generalised lymphadenopa-
thy and bone marrow involvement [12]. The course of follicular lymphoma is quite variable.
Some patients have waxing and waning disease for years without the need for therapy [13],
whereas others require treatment for more disseminated and rapidly growing disease. The
disease is characterised by repeated relapses, finally leading to the patients’ death after median
7 to 10 years for those with initially stage III and IV disease. Unfortunately, overall survival of
patients with follicular lymphoma has not changed in spite of many different treatment ap-
proaches over the past decades [14].
Considering prognostic models, first the International Prognostic Index was reported,
which was originally developed for patients with aggressive non-Hodgkin’s lymphomas [15].
Later on a predictive model for follicular lymphoma has been reported, mentioning six adverse
prognostic factors, i.e. age > 60 years, male sex, two or more extranodal sites involved,
elevated serum lactate dehydrogenase (LDH) level, presence of systemic symptoms and an
erythrocyte sedimentation rate of 30 or more mm/h [16].
Histologic transformation of follicular lymphoma from an indolent to a diffuse aggressive
lymphoma occurs frequently, and is associated with rapid progression of lymphadenopathy,
infiltration of extranodal sites, development of systemic symptoms, elevated LDH, and often a
poor prognosis.
Treatment
Compared to patients with aggressive lymphoma, patients with follicular lymphoma in general
have a reasonably long survival, measured in years, even if left untreated [13]. However, these
patients are usually incurable with conventional treatment. Thus, in approaching patients with
follicular lymphoma one must consider the indications for treatment: instead of cure, alleviation
of symptoms should then be the goal of treatment.
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early stage disease
The minority of patients with follicular lymphoma, i.e. about 15%, presents with stage I or II
disease. Radiotherapy in a curative dose (36-40 Gray) on the involved lymph nodes is the
treatment-of-choice for these patients. This treatment results in about 40% of patients being
disease free at more than 10 years [17,18]. Results for patients with stage I disease are in
general better than for those with stage II. Thus a subset of patients presenting with early stage
follicular lymphoma are curable with radiotherapy.
advanced stage disease
The majority of follicular lymphoma patients presents with stage III and IV disease. Due to the
long natural history of follicular NHL and due to the general lack of symptoms at diagnosis,
close observation can be the initial approach to a considerable part of these patients. It is
justified in patients without systemic symptoms, without signs of bone marrow suppression,
and without mechanical difficulties caused by lymphomas. Thus, the treatment-free period is
prolonged, during which the risk of the lymphoma becoming drug-resistant due to continuous
exposure to therapy is excluded. This initial wait-and-see policy does not impair the prognosis
[13,14,19]. Once treatment is indicated, a choice must be made of several therapies, which will
be discussed below.
standard chemotherapy
Follicular lymphomas are very sensitive to both single agent (e.g. chlorambucil) and combina-
tion chemotherapy (e.g. cyclophosphamide, vincristine and prednisone (CVP)). These regi-
mens result in a remission rate of 50-80% and a median progression-free survival of 2-3 years
[14,20]. At relapse, the lymphoma is usually still sensitive to such therapies, however, the
progression-free survival progressively decreases with each subsequent relapse [20]. More
intensive treatment with anthracycline-containing chemotherapy increases the rate and
duration of remission, but it does not improve survival [21].
interferon-alpha
Interferon-alpha (IFN) has activity when added to chemotherapy in advanced stage follicular
lymphoma. The role of IFN, given in combination with chemotherapy or as maintenance
treatment after achieving a remission is not quite clear, as literature is in part contradicting. In
general a prolongation of progression-free, but not overall survival is reported by IFN added to
chemotherapy. Only two studies reported an improved overall survival as well, due to the
combination of IFN to anthracycline-containing chemotherapy [22] and due to IFN mainte-
nance therapy for follicular lymphoma in remission [23].
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Side effects of IFN are common: fatigue, flue-like symptoms, psychic changes and
polyneuropathy may lead to dose reduction in up to a third of patients [22]. Toxicity of
treatment with IFN and lack of prolongation of overall survival question the use of IFN in
treatment of follicular lymphoma patients.
purine analogues
The purine analogues cladribine (2-CDA) and fludarabine, acting on slowly proliferating
malignancies, are effective in follicular lymphoma. When given as single agent these drugs can
induce remissions, usually incomplete, in at least half of patients, in particular the previously
untreated ones  [24,25]. The efficacy of the combination of purine analogues with other
chemotherapy for follicular lymphoma is being investigated.
Toxicity of purine analogues requires special attention. Infectious complications occur in
about 50% of pre-treated patients, and may consist of serious opportunistic infections with
Pneumocystis carinii, fungi, yeasts, mycobacteria, Listeria monocytogenes, and herpes viruses
[26]. An explanation for the increased susceptibility to infections may be that the number of T-
helper lymphocytes is strongly depressed for more than one year after treatment with purine
analogues [26].
monoclonal antibodies
In the last decade monoclonal antibodies, especially the humanised anti-CD20 rituximab, are
emerging in treatment of patients with follicular lymphoma. Rituximab results in a remission,
usually being partial, in about 50% of pre-treated patients [27,28]. Responses are even up to
about 70% when rituximab is given as initial therapy [29], or in combination with chemo-
therapy [30]. Toxicity of rituximab is largely infusion related, with fever, rigors and hypotension,
usually associated with the first infusion; furthermore, depletion of circulating B-lymphocytes
during months after treatment is known. Clearance of t(14;18) positive cells from blood and/or
bone marrow samples after treatment with rituximab has been reported, although there is no
consensus yet on its association with improved response rate [28-30].
radio-immunotherapy
Monoclonal antibodies conjugated with radioactive isotopes can be used to deliver targeted
radiotherapy to lymphoma bearing areas. An example of these radio-immunoconjugates is
tositumomab, a murine anti-CD20 monoclonal antibody conjugated with radioactive Iodine-
131.
Introduction
15
The first reports on tositumomab show encouraging results with response rates of 71%
with a median progression-free survival of 12 months in relapsed or even chemotherapy
refractory B-cell lymphoma [31]. Studies on myeloablative doses of tositumomab and chemo-
therapy followed by autologous stem cell transplantation are ongoing.
antisense therapy
Still experimental but attractive is the use of antisense therapy directed to the bcl-2 gene
involved in the pathogenesis of follicular lymphoma.
autologous stem cell transplantation
High-dose chemotherapy - with or without total body irradiation - followed by autologous
bone marrow or peripheral blood stem cell transplantation (SCT) induces remissions in 40-
60% of patients with relapsed follicular lymphoma during a relative short follow-up of 3-4 years
[32-34]. It is unclear whether this intensified treatment approach will also result in a prolonged
survival. Since the harvested bone marrow is often contaminated with NHL cells, techniques
have been used to purge the marrow in vitro. It is controversial whether this effort decreases
the relapse risk after autologous SCT. An association has been reported between clearance of
t(14;18) positive cells from blood and/or bone marrow after autologous SCT, i.e. a molecular
response, and a clinical response [34-36].
allogeneic stem cell transplantation
In theory, cure might be anticipated by treatment of follicular lymphoma patients with myelo-
ablative therapy, followed by infusion of stem cells derived from an HLA-compatible donor.
First, the allogeneic stem cell graft is not contaminated with malignant cells. Second, patients
may benefit from the so-called ‘graft-versus-lymphoma’ effect. However, there is concern about
the transplant-related morbidity and mortality, as well as graft-versus-host disease. In relapsed
follicular lymphoma allogeneic SCT resulted in a three years disease-free and overall survival in
49%, with a three years relapse rate of only 16% [37]. Prognostic favourable variables are a
good performance status, young age, and chemotherapy sensitive disease before transplanta-
tion. Outcome of patients may improve by performing allogeneic stem cell transplantation
earlier in the course of disease, or by the use of non-myeloablative conditioning regimens.
In case of a relapse after allogeneic SCT, remission can still be induced by infusion of
lymphocytes of the original stem cell donor [38 = chapter 5 of this thesis].
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This thesis
The present thesis focuses on the potential role of molecular diagnostics, i.e. the quantitative
monitoring of t(14;18) positive cells, in the treatment of follicular lymphoma patients. Analysis
of circulating lymphoma cells might be valuable in early evaluation of the efficacy of (new)
therapies, because it may take years before clinical observations can show any survival benefit,
due to the indolent course of disease. Until now questions remain on the clinical significance of
the presence, and if so in what quantity, of circulating lymphoma cells [29,30,34,36,38-48].
Studies presented in thesis, try to rationalise the use of molecular diagnostics in follicular
lymphoma.
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Summary
We present the clinical results of allogeneic bone marrow transplantation (BMT) with T-cell
depleted grafts from HLA-matched sibling donors in patients with poor-risk relapsed low-grade
non-Hodgkin’s lymphoma (NHL). Poor-risk was defined as relapse within 12 months after or
progression during prior treatment. Conditioning regimen consisted of cyclophosphamide and
total body irradiation with or without additional idarubicin. Donor marrow was depleted of T-
lymphocytes using counterflow centrifugation. Post-BMT prophylaxis of graft-versus-host
disease (GvHD) consisted of cyclosporin A. Fifteen patients with a median age of 47 years
(range 30-57) were transplanted. All patients engrafted. After a median follow up of 36 months
(range 9-78), 10 patients were alive and in complete remission (CR). Two of them had relapsed
after BMT but re-entered CR following infusions of leukocytes from the original bone marrow
donor. Five patients died; causes of death were cardiomyopathy (n=1), chronic GvHD (n=1)
and infection during chronic GvHD (n=3). We conclude that allogeneic T-cell depleted bone
marrow transplantation is an efficacious treatment for patients with poor-risk relapsed low-
grade NHL. Infusions of donor leukocytes re-induced CR in the two patients with relapse after
BMT.
Allogeneic bone marrow transplantation
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Introduction
After first relapse, patients with follicular non-Hodgkin’s lymphoma (NHL) of low-grade
malignancy have a median survival of only 4-6 years [1,2]. While high-dose treatment followed
by autologous stem cell support appears to prolong progression-free survival, improvement of
overall survival has not been demonstrated yet [3-8]. Allogeneic bone marrow transplantation
(BMT) is an efficacious therapy for several haematological malignancies with curative potential.
Allografting patients suffering from malignant lymphomas with bone marrow involvement has
the advantage of avoiding re-infusion of residual malignant cells, which may contribute to
subsequent relapse. Furthermore, allogeneic BMT may induce a graft-versus-lymphoma effect
[9,10]. Literature data on allogeneic BMT in low-grade NHL are scarce, mainly due to the
advanced age of the patients, who have a reasonable life expectancy being treated with less
toxic regimens. Furthermore, human leukocyte antigen (HLA) matched sibling or unrelated
donors are available for only a minority of patients.
In a recent study on allogeneic BMT with unmanipulated grafts in 10 patients with re-
lapsed or refractory low-grade NHL a complete remission rate of 80% was attained after a
median follow-up of 27 months without any relapse, but at the cost of a transplant related
mortality rate of 20% [11]. Others reported comparable and even higher mortality rates after
BMT [12,13].
Here, we present our results of allogeneic BMT with T-cell depleted grafts in 15 patients
with poor-risk relapsed low-grade NHL.
Patients and methods
From December 1989 to September 1996 fifteen consecutive patients with poor-risk relapsed
low-grade NHL received myelo-ablative treatment followed by transplantation of T-cell de-
pleted bone marrow from an HLA-A, B and DR-identical, mixed lymphocyte culture (MLC)-
negative sibling donor. Eligibility criteria for the BMT program included: histologically proven
follicular centroblastic-centrocytic or B-lymphocytic NHL of low-grade malignancy classified
according to the Kiel classification (Working Formulation: follicular predominantly small cleaved
or mixed cell lymphoma or small lymphocytic lymphoma consistent with chronic lymphatic
leukaemia; REAL classification: follicular center cell grade I-II or B-cell chronic lymphatic
leukaemia/small lymphocytic lymphoma [14], all cases were reviewed by MJJTB); a last
progression-free interval of ≤12 months or progressive disease during the last chemotherapy
schedule; age <60 years; preserved cardiac function (nuclear left ventricular ejection fraction ≥
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≥ 50%); a pulmonary CO2 diffusion capacity of >50% of predicted; WHO-performance status
0,1 or 2; no central nervous system involvement and an H.I.V.-1-negative status.
Prior to BMT all patients were tested for continued chemotherapy-responsiveness. The
type of chemotherapy was left to the discretion of the referring physician and consisted of
either a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like regimen (n=11),
chlorambucil (n=3) or DHAP (dexamethasone, high-dose cytarabine, cisplatin, n=1). All
patients were conditioned for BMT with cyclophosphamide (60 mg/kg i.v. daily on day -6 and -
5), and total body irradiation (4.5 Gy daily on day -2 and -1). As part of an ongoing study in
our department on improving efficacy of the conditioning schedule, 11 patients received
additionally idarubicin (42 mg/m2 continuously i.v. for 48 hours on day -12 and -11) [15].
Donor marrow was depleted of 98% of T-lymphocytes using counterflow centrifugation
[16]. Post-transplantation graft-versus-host disease (GvHD) prophylaxis consisted of
cyclosporin A (3 mg/kg/day i.v. from day -1 up to day 14, then 2 mg/kg/day i.v.; as soon as
patients could take cyclosporin A orally, it was given in a dose of 6 mg/kg/day up to day +75,
then tapered off within 2-3 weeks). The patients were nursed in single rooms with filtered air
under positive pressure in reverse isolation. Selective gut decontamination consisted of
ciprofloxacin and oral amphotericin-B. Further prophylaxis included nasal inhalations of
amphotericin-B for Aspergillus fumigatus, acyclovir (up to day +60) for herpes viruses, and
cotrimoxazole or Pentamidine (up to 6 months after BMT) for Pneumocystis carinii. When the
haemoglobin level and platelet counts dropped below 6.0 mmol/l and 15 x 109/l respectively,
transfusions with irradiated and leukocyte depleted blood products were given.
Prior to BMT patients were restaged by physical examination, chest X-ray, computed
tomography of chest and abdomen, and aspirate and biopsy of the bone marrow. After BMT,
response was assessed at 3 months and at regular intervals thereafter. The extent of the
restaging was guided by signs and symptoms. Complete remission (CR) was defined as
disappearance of all disease-related signs and symptoms; partial remission (PR) as decrease of
at least 50% of all measurable lesions. An increase of 25% or more or appearance of new
lesions or symptoms was called progressive disease (PD). Stable disease (SD) included those
responses not being classified as CR, PR or PD.
The clinical manifestations of acute GvHD were graded I to IV according to the criteria
described by Glucksberg et al [17]. Chronic GvHD was classified as limited or extensive [18].
Data on the incidence of GvHD and on predisposing factors to GvHD were compared to
that obtained in patients with other haematological malignancies who received allogeneic BMT
from a genetically identical sibling donor in our institution during the same study period.
Factors included in the analysis were age of patients at BMT, number of T-lymphocytes left in
the graft, serum levels of immunoglobulins just prior to BMT, age of the donor, and sex
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mismatch between patient and donor. The chi-squared test was used for testing differences in
incidence of GvHD between the different groups of patients, whereas statistical analysis of the
non-parametric factors possibly contributing to GvHD was performed by the Kruskal-Wallis test.
To determine whether diagnosis, age of patient and donor, sex of patient and donor and sex
mismatch, immunoglobulin level, T-cell dose and intensity of conditioning regimen were
independent predictors of acute and chronic GvHD, a multivariate analysis was performed
using the stepwise logistic regression model. In this multivariate analysis we excluded the group
of patients with multiple myeloma because of interfering levels of paraprotein in the immu-
noglobulin levels. A p-value of <0.05 was considered statistically significant. Event-free and
overall survival estimates were calculated using the Kaplan-Meier method. The follow-up
period for this analysis ended May 1st, 1997.
Results
Patient characteristics
Table 1 shows characteristics of the 15 patients before allogeneic BMT. At initial diagnosis the
median age of the patients (eight males and seven females) was 43 years (range 28-54 years).
Ten patients had stage IV disease, nine of them with bone marrow involvement. Thirteen
showed low-grade follicular centroblastic-centrocytic histology in the initial biopsy specimens
and two low-grade B-cell small lymphocytic histology. Seven patients had been pretreated with
only one chemotherapy regimen, four patients with two, three patients with three, and one with
four different schedules. Ten patients had responded to the last chemotherapy regimen (CR,
n=2 and PR, n=8) for a median of 9 months (range 1-12 months).
Characteristics of the patients at the time of BMT are presented in table 2 All patients still
had histologically proven low-grade NHL. The median interval between initial diagnosis and
BMT was 36 months (range 14-80 months). At transplantation the median age of the patients
was 47 years (range 30-57 years). Before BMT all patients were treated with debulking chemo-
therapy; response was evaluated in 13 of them. Four patients were in nodal CR with bone
marrow involvement in one of them; eight patients were in nodal PR with bone marrow
involvement being present in four, absent in two and unknown in two. The remaining patient
had SD after debulking therapy. None of the patients had bulky disease (a mass of more than
10 cm) or elevated serum LDH at the time of BMT.
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Outcome
All patients showed engraftment of the donor marrow. The median time to recovery of
leukocytes >1.0x109/l was 19 days (range 12-26 days) and of platelets >20x109/l 21 days
(range 12-103 days).
After a median follow-up of 36 months (range 9-78 months) after transplantation, 10
patients (67%) were alive and five (33%) had died (table 3). Eight of 10 living patients were in
continuous CR. Two patients relapsed at 22 and 25 months after BMT respectively. The
calculated 3-year event-free survival, defined as the absence of relapse, progressive disease or
death, whatever came first, was 39% with a calculated overall survival of 59%.
Treatment of relapse with donor leukoocyte infusions
The two patients with relapse were treated with infusions of 0.5x108 CD3+ lymphocytes per kg
body weight from the original bone marrow donor. The first of these two patients (#8), who
did not suffer from GvHD after BMT, relapsed 22 months after BMT with localisations in
supraclavicular, axillary, intrathoracal, intraabdominal and inguinal lymph nodes as well as
Table 1. Initial patient characteristics.
pat. age (yrs) sex histology stage bone previous response to
nr at diagn. at diagn. marrow treatment last treatment
at diagn. in sequence (duration)
1 41 M foll CB-CC IVB positive Chl/IFNα failure
2 28 M foll CB-CC IVA positive CHVmP/BV PR (12 mos)
3 38 M foll CB-CC IIIA negative CVP, CHVmP/BV, Chl/P SD
4 34 F foll CB-CC IIIA unknown CHOP, Chl/P, Chl/IFNα PR (11 mos)
5 44 F foll CB-CC IIA negative CVP, Chl failure
6 45 M foll CB-CC IVA positive Chl/P PR (2 mos)
7 43 M foll CB-CC IVA negative CVP failure
8 46 F foll CB-CC IVA positive CVP+IFNα, Chl failure
9 41 F foll CB-CC IIA unknown CHOP, CNOP CR (9 mos)
10 52 M B-lymphocytic IVA positive Chl, IFNα PR (9 mos)
11 38 F foll CB-CC IVA positive CHVmP/BV PR (6 mos)
12 54 F foll CB-CC IVB positive CVP, Flu, CHVmP/BV, VP PR (1 mo)
13 46 F foll CB-CC IIIA negative Chl/P CR (11 mos)
14 47 M B-lymphocytic IVA positive Chl/P, CVP, Flu PR (8 mos)
15 30 M foll CB-CC IVB positive CVP PR (6 mos)
Abbreviations: M = male; F = female; foll CB-CC = follicular centroblastic-centrocytic;
IFNα = interferon-alpha; CHVmP/BV = cyclophosphamide, doxorubicin, teniposide, prednisone,
bleomycin, vincristine; CVP = cyclophosphamide, vincristine, prednisone; Chl/P = chlorambucil,
prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; Chl/IFNα = chlorambucil,
interferon-alpha; CVP+IFNα = CVP + interferon-alpha maintenance; CNOP = cyclophosphamide,
mitoxantrone, vincristine, prednisone; Flu = fludarabine; VP = vincristine, prednisone;
CR = complete remission; PR = partial remission; SD = stable disease; mo(s) = month(s)
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bone marrow, all sites also involved initially. Histological examination of a lymph node showed
persistent follicular NHL of low-grade malignancy. Three months after donor leukoocyte
infusions (DLI) this patient showed a nodal PR, and she attained a nodal CR 9 months after
DLI, which is continuing at six months. She developed only limited chronic GvHD after DLI.
The second patient (#9), who had no acute GvHD but limited chronic GvHD after BMT,
relapsed 25 months after BMT with localisations in axillary and intrathoracal lymph nodes, all
areas also involved initially. No signs of histological dedifferentiation to a higher malignancy
grade were noted in the removed lymph node. She achieved a nodal CR three months after
DLI, which continued at four months. Limited chronic GvHD was observed after DLI in this
patient.
Toxicity
One fatal complication occurred in the immediate post-transplant period, namely cardiomy-
opathy 1 month after BMT (#3). Four patients died at a later stage. One patient (#12), who
had been pretreated with the purine analogue fludarabine, died of refractory extensive chronic
Table 2. Patient characteristics at BMT.
patient age (years) interval diagnosis debulking therapy nodal response bone marrow
number at BMT to BMT (months) at BMT involvement at BMT
1 45 47 Chl/IFNα PR negative
2 30 31 Chl PR positive
3 43 60 CHVmP PR negative
4 40 69 DHAP CR positive
5 47 37 CHVmP/BV PR positive
6 47 16 CHVmP/BV PR positive
7 45 23 CHVmP/B CR negative
8 48 29 CHOP CR negative
9 48 80 CNOP CR unknown
10 57 67 Chl SD positive
11 39 14 CVP unknown positive
12 55 17 CVAP PR unknown
13 49 36 CVP unknown positive
14 51 57 CVAP PR positive
15 31 15 CHVmP/BV PR unknown
Abbreviations: BMT = allogeneic bone marrow transplantation; Chl/IFNα = chlorambucil, interferon-
alpha; Chl = chlorambucil; CHVmP-BV = cyclophosphamide, doxorubicin, teniposide, prednisone,
bleomycin, vincristine; DHAP = dexamethasone, high-dose cytarabine, cisplatin; CHOP = cyclophospha-
mide, doxorubicin, vincristine, prednisone; CNOP = cyclophosphamide, mitoxantrone, vincristine,
prednisone; CVAP = cyclophosphamide, vincristine, cytarabine, prednisone; CR = complete remission;
PR = partial remission; SD = stable disease
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GvHD 7 months after BMT. Three others died of infection 10, 21 and 21 months after BMT, all
during a period with chronic GvHD. One fatal infection was an pneumonia caused by cytome-
galovirus (CMV) and Staphylococcus aureus in patient #1 suffering from extensive chronic
GvHD, who was hypogammaglobulinaemic and who had been pretreated with interferon-
alpha during 44 months until three months prior to BMT. Another patient (#4) died of septi-
caemia with a clinical picture resembling pneumococcal septicaemia in a functionally asplenic
patient who did not take amoxicillin prophylaxis. At that time, she had only limited chronic
GvHD. This patient had been pretreated with interferon-alpha for seven months until 14
months before BMT. The last fatal infection was a suspected but not proven fungal pneumonia
in patient #11 with extensive chronic GvHD and hypogammaglobulinaemia. Autopsy has
been performed in three of the five patients, showing no signs of active NHL in either of them.
Two of the 10 surviving patients developed CMV-disease, being a CMV interstitial pneu-
monitis in one and a CMV gastritis in the other patient, 3 and 5 months after BMT respectively.
Both patients were successfully treated with ganciclovir and CMV-hyperimmune globulin.
One patient suffered from avascular femoral head necrosis at both sides while being
treated with corticosteroids for limited chronic GvHD 11 months post BMT, necessitating two
femoral head prostheses.
Table 3. Outcome of BMT.
pat. conditioning nr of infused acute chronic outcome cause of death
nr regimen T-lymphocytes GvHD GvHD (months)
(x106/kg)
1 ida/cyclo/TBI 0.40 grade II extensive death (21) CMV, Staph. aur.
2 cyclo/TBI 0.70 none none CCR (78+)
3 cyclo/TBI 0.90 grade I n.a. death (1) cardiomyopathy
4 cyclo/TBI 1.40 grade II limited death (21) septicaemia
5 cyclo/TBI 1.40 grade II limited CCR (65+)
6 ida/cyclo/TBI 0.90 grade I extensive CCR (45+)
7 ida/cyclo/TBI 1.00 grade II limited CCR (41+)
8 ida/cyclo/TBI 0.70 none none relapse (22)
after DLI CR (6+)
9 ida/cyclo/TBI 0.70 none limited relapse (25)
after DLI CR (4+)
10 ida/cyclo/TBI 0.80 grade II limited CCR (23+)
11 ida/cyclo/TBI 0.79 grade II extensive death (10) suspected fungus
12 ida/cyclo/TBI 0.71 grade II extensive death (7) GvHD
13 ida/cyclo/TBI 0.75 grade I extensive CCR (14+)
14 ida/cyclo/TBI 0.70 none limited CCR (14+)
15 ida/cyclo/TBI 0.76 grade II extensive CCR (9+)
Abbreviations: GvHD = graft-versus-host disease; ida = idarubicin; cyclo = cyclophosphamide;
TBI = total body irradiation; CCR = continuous complete remission; CMV = cytomegalovirus;
Staph. aur. = Staphylococcus aureus; DLI = donor leukocyte infusions
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GvHD
Eleven of the 15 patients developed acute GvHD classified as grade I in three patients and
grade II in eight. Twelve out of the 14 patients at risk developed chronic GvHD, which was
limited in six patients and extensive in six. The incidence of GvHD was higher than in patients
who received BMT for other indications in our department. For that reason we studied several
risk factors for development of GvHD in the patients with low-grade NHL and others. Table 4
shows the results of the analysis in these patients, all transplanted with T-cell depleted bone
marrow from a HLA-identical sibling in the period between December 1, 1989 and June 1,
1996. Data are given for patients with low-grade NHL, intermediate or high-grade NHL, acute
myeloid leukaemia (AML) in first CR, acute lymphoblastic leukaemia (ALL) in first or second
CR, chronic myeloid leukaemia (CML) in first chronic phase, and multiple myeloma (MM).
The patients with low-grade NHL had significantly more often acute GvHD ≥ grade II than
those with leukaemia: 50% vs 20% (p=0.014). The low-grade lymphoma patients also had
significantly more often extensive chronic GvHD than leukaemia patients: 38% vs 12%
(p=0.016). Age of patients at BMT and age of their donors differed significantly between the
groups (p=0.0037 and p=0.0072 respectively). Patients with low-grade NHL were significantly
older and received progenitor cells from an older donor compared to those with intermediate
or high-grade NHL and leukaemia, but not multiple myeloma. We could neither find significant
differences in patient-donor sex mismatch between the patient groups, nor in the number of T-
lymphocytes in the marrow graft. Serum levels of gammaglobulin, IgG, IgA and IgM immedi-
ately prior to BMT were significantly lower in low-grade lymphoma patients than in AML
patients (p<0.01 for each immunoglobulin) and than in CML patients (p<0.0001 for each
immunoglobulin). Remarkably, we did not find significant differences between levels of these
immunoglobulins between patients with low-grade NHL and those with ALL (p=0.29, p=0.56,
p=0.082 and p=0.063 respectively) or those with intermediate or high-grade NHL (p=0.90,
p=0.66, p=0.83 and p=0.48 respectively). No significant differences in intensity of condition-
ing regimens were observed between the patient groups, nor in the post BMT
immunoprophylaxis.
In the multivariate analysis, performed on all patient groups except those with MM, a
diagnosis of non-Hodgkin’s lymphoma and additional idarubicin in the conditioning regimen
were the only significant variables contributing to the risk of acute GvHD ≥ grade II (p=0.01
and p=0.048 respectively); a diagnosis of NHL and a female donor were the only significant
variables predictive of an increased risk of extensive chronic GvHD (p=0.02 and p=0.03
respectively). Age at BMT and serum immunoglobulin levels failed to reach a statistically
significant predictive power.
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Table 4. Characteristics and outcome of patients transplanted with T-cell depleted bone marrow from an HLA-identical sibling donor between December 1,
1989 and June 1, 1996.
low-grade NHL intermediate or ALL CR1+2 AML CR1 ML CP1 MM
high-grade NHL
number of patients 14 10 28 44 32 15
acute GvHD grade >2 50% 40% 14% 30% 13% 60%
chronic GvHD extensive 38% 25% 13 14% 10% 18%
mean age ± SD at BMT (yrs) 46.1 ± 6.8 34.7 ± 10.8 31.3 ± 12.03 6.7 ± 11.7 39.2 ± 9.3 43.9 ± 5.9
mean age ± SD of donor (yrs) 46.0 ± 9.5 29.2 ± 10.1 32.6 ± 13.53 7.0 ± 11.9 37.9 ± 11.5 41.3 ± 7.7
patient - donor sex mismatch 43% 90% 50% 50% 56% 33%
mean number of T-lymphocytes ± SD
infused at BMT (x106/kg) 0.85 ± 0.27 0.93 ± 0.19 0.95 ± 0.25 0.86 ± 0.20 0.85 ± 0.24 0.95 ± 0.22
mean gammaglobulin ± SD
before BMT (g/l)   5.7 ± 1.5   6.1 ± 1.8   6.3 ± 1.9 10.7 ± 3.2 10.7 ± 2.8
mean IgG ± SD before BMT (g/l) 6.38 ± 2.02 6.58 ± 2.70 6.64 ± 1.67     11.23 ± 2.83     10.50 ± 2.16
mean IgA ± SD before BMT (g/l) 0.82 ± 0.46 0.73 ± 0.24 1.23 ± 0.69 1.88 ± 0.77 2.06 ± 0.91
mean IgM ± SD before BMT (g/l) 0.41 ± 0.27 0.53 ± 0.18 0.82 ± 0.73 0.87 ± 0.45 1.60 ± 1.11
ida in conditioning 71% 70% 61% 68% 81% 40%
Abbreviations: NHL = non-Hodgkin’s lymphoma; ALL CR1+2 = acute lymphoblastic leukaemia in first or second complete remission; AML CR1 = acute
myeloid leukaemia in first complete remission; CML CP1 = chronic myeloid leukaemia in first chronic phase; MM = multiple myeloma; GvHD = graft-versus-
host disease; ida = idarubicin. In MM patients data of immunoglobulin levels are not given because of interfering paraprotein levels.
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Discussion
This is the first report on the outcome of allogeneic BMT with T-cell depleted marrow grafts in
patients with poor-risk low-grade NHL. All evaluable patients achieved complete remission.
Only two patients developed a relapse after BMT; both patients re-entered CR after infusions of
donor-derived peripheral blood leukocytes. These encouraging results from a single-center
experience require careful consideration.
It is well known that intensive chemotherapy such as the ProMACE-MOPP schedule [19]
or high-dose treatment with autologous stem cell support [3-8] result in high CR rates in
patients with low-grade NHL. According to results obtained with autologous BMT in patients
with relapsed intermediate or high-grade NHL [20] we selected only those patients for the
allogeneic BMT program who still were responsive to conventional chemotherapy regimens.
Therefore, it may not be too surprising that initially high CR rates were observed. Comparably
high CR rates after allogeneic BMT with unmanipulated marrow grafts have been reported in
other series [11-13]. The question whether even patients with chemotherapy-refractory disease
could benefit from allogeneic BMT cannot be answered from our series. In the reports of Van
Besien et al and Molina et al, some patients with refractory disease were included with appar-
ently similar outcome. However, the number of included patients was far too small to permit a
meaningful conclusion. Hence, until proven otherwise, allogeneic BMT should probably be
reserved for patients with disease still responsive to chemotherapy.
The duration of remission after BMT exceeded that of prior remissions in all 10 surviving
patients. This finding is of special note since prior to BMT all patients had progressive disease
within 12 months after previous treatment. Normally, the duration of remission decreases
progressively with subsequent conventional treatment regimens [2]. Prolongation of remission
observed after BMT, may be attributed solely to the intensity of the conditioning regimen.
Comparable results of prolonged remissions have been reported after autologous BMT [3-
5,7,8,21,22].
One of the most striking findings in this study is the outcome of the two patients who
relapsed and then again attained CR after infusions of leukocytes from the original bone
marrow donor. These results strongly support the existence of a graft-versus-lymphoma effect.
In both patients evaluable tumour lesions showed a decrease after DLI until CR was reached
eventually. We believe that the favourable results of allogeneic BMT cannot be explained
merely on the basis of the intensive conditioning regimen before BMT, but also on immunology
mechanisms after BMT [23]. As already shown for acute leukaemia, chronic myeloid leukae-
mia and multiple myeloma, one of the additional beneficial effects of BMT, whether or not
followed by DLI, is the immune-mediated graft-versus-tumour effect [24-27]. Especially in
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patients with relapsed chronic myeloid leukaemia post-BMT, DLI induce renewed remission in
the majority of patients, whereas patients with acute leukaemia respond less favourably to DLI.
This difference in response rate could be due to a higher tumour mass at the time of DLI in the
latter, whereas in the former the DLI are often already given at cytogenetic relapse. However,
the patients with low-grade NHL in the present series had clinically active disease that re-
sponded to DLI without prior chemotherapy, suggesting that other factors than tumour mass
per se might play a role. The divergent results between different underlying malignancies may
also be due to different expression of target antigens with which donor leukocytes have to
react. In addition, donor leukocytes may induce production of cytokines and cellular mediators
involved in the allogeneic graft-versus-tumour reaction. These questions remain open for
further research.
In patients with low-grade NHL, special attention should be paid to toxicity of new
treatment modalities since until yet no curative treatment options are available, but mild
palliative therapies are. Five patients (33%) have died due to BMT-related complications, only
one of them in the immediate (<3 months) post-BMT period. These data roughly match
mortality rates in other reports [11-13]. Despite physical T-cell depletion of the marrow grafts
the incidence of graft-versus-host disease in our low-grade NHL patients was remarkably high,
as compared to leukaemia patients transplanted with T-cell depleted marrow grafts in our and
other institutions [28,29]. Acute GvHD of at least grade II was found in eight patients (53%)
and extensive chronic GvHD in six of 14 patients at risk (43%). GvHD certainly has contrib-
uted to the development of fatal infections in these patients. Since there are no reports in
literature on the outcome of T-cell depleted BMT in low-grade NHL, we compared data on the
incidence and putative risk factors of acute and chronic GvHD of the study group with that of
other patient groups treated with BMT at our institution. Patients with low-grade NHL had
significantly more often both acute GvHD ≥ grade II and extensive chronic GvHD than those
with leukaemia. Low-grade lymphoma patients were older and had an older donor than those
with leukaemia and those with intermediate or high-grade NHL. Advancing age of the recipient
is a well-known risk factor for acute GvHD [30,31]. Since most patients with low-grade NHL
are >40 years of age, advanced age will remain a major risk factor. Remarkably, as compared
to the low-grade lymphoma patients, patients with multiple myeloma had comparably high
incidence rates of GvHD, and were at advanced age at the time of BMT too. However, in the
group of patients with NHL of higher malignancy grades, comparable incidence rates of GvHD
occurred while the mean age of these recipients was lower than that of those with low-grade
lymphomas. Thus, other factors are responsible for the apparently increased incidence of
GvHD in NHL patients. In three groups of patients with lymphoid malignancies (low-grade
NHL, intermediate or high-grade NHL, acute lymphocytic leukaemia) the mean immunoglobu-
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lin levels prior to BMT were significantly lower than that in patients with myeloid leukaemias.
This points at an impaired humoral immune status in patients with a lymphoid malignancy.
Because of interfering paraprotein levels the immunoglobulin levels in multiple myeloma
patients cannot be compared with other patients, but levels of immunoglobulins other than the
paraprotein are generally decreased in multiple myeloma. Apart from this impaired function of
B-lymphocytes in recipients, we can offer only circumstantial evidence for a concomitant
diminished T-cell function. None of the patients with lymphoid malignancies developed graft
rejection. Graft rejection is mediated by competent recipient T-lymphocytes and occurs in
approximately 5% of BMT with T-cell depletion by counterflow centrifugation [28]. Prior
systemic treatment might have compromised recipient T-cell numbers and T-cell function even
further. Purine analogues, increasingly used in the treatment of patients with low-grade NHL,
cause a long-term depletion of CD4+ T-cells [32]. In our series, only two patients have been
pretreated with fludarabine, one of whom developed acute GvHD grade II and extensive
chronic GvHD, whereas the other patient did not develop acute GvHD but did develop limited
chronic GvHD. Conclusions cannot be drawn from these limited data. Recently, a potentially
protective effect against acute GvHD by fludarabine has been suggested in a group of 15
patients at risk of GvHD after BMT for advanced chronic lymphocytic leukaemia [33]. There-
fore in future studies special attention should be given to the role of purine analogues given
prior to BMT.
In multivariate analysis of our patients transplanted for leukaemia or NHL in our depart-
ment a diagnosis of NHL and intensified conditioning by additional idarubicin were significant
predictors of acute GvHD ≥ grade II, whereas a diagnosis of NHL and a female donor sex were
significant predictors of extensive chronic GvHD. Thus, we confirm earlier findings that
intensification of conditioning regimen is associated with an increase in serious acute GvHD
[34,35], despite T-cell depletion of the graft.
These data support the concept of an impaired immune status of patients with low-grade
NHL, therefore predisposing to development of GvHD despite T-cell depletion of the marrow
grafts. This conclusion may have consequences for future allogeneic transplantation programs
since stem cells derived from peripheral blood instead of bone marrow are increasingly used
and are known to contain a higher numbers of T-lymphocytes, representing effector cells of
GvHD [36,37]. However until now no increase in GvHD has been reported in patients
transplanted with unmanipulated peripheral blood derived stem cell grafts compared to bone
marrow derived stem cell grafts [38,39]. Finally, BMT with grafts from matched unrelated
donors (MUD) is more likely to produce GvHD and on the other hand carries a higher risk of
rejection [40,41]. As long as consistently favourable long-term results of BMT are lacking,
MUD-BMT should probably be restricted to highly selected young patients with a perfectly
matched donor.
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Allogeneic BMT is emerging as a promising treatment modality for selected patients with
early relapsed or progressed NHL of low-grade malignancy. At present, allogeneic BMT is the
only treatment with curative potential. Because of the relatively high age and
immunocompromised status of the patients, the risk of toxicity in terms of both morbidity and
mortality is increased. More rigorous attempts to prevent GvHD, careful use of peripheral stem
cells, strict patient and donor selection and possibly prophylactic substitution of
immunoglobulins, may further improve the outcome. In case of relapse after BMT, infusions of
leukocytes of the original stem cell donor appears to be the treatment of choice.
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Abstract
A quantitative analysis was developed to monitoring the efficacy of intensive treatment
modalities in follicular non-Hodgkin’s lymphoma (NHL) patients on a molecular level. The
lymphoma associated disease marker t(14;18) is present in most follicular NHL patients, and
can be detected by assays based on the polymerase chain reaction (PCR). This allows sensitive
detection to a limit of about 1 lymphoma cell per 150.000 cells. The assay presented has
several advantages over convential PCR analysis. It is a real-time quantitative assay with a
detection level that equals the detection level of convential PCR analysis. The amplification
and detection of specific PCR products occurs in a closed system due to the application of an
internal dual-labelled non-extendible probe, thereby reducing the risk of false positivity.
Positivity of reaction is determined at the cycle threshold in the exponential phase of the
reaction, and is directly proportional to initial amount of template present. To correct for false
negativity, a PCR on the ß-actin gene was used as an amplification control. The t(14;18) and
ß-actin amplification reaction were shown to have equal efficiency on an identical template.
This allows normalisation of the t(14;18) PCR signal, as a measure of lymphoma cells, by the
ß-actin PCR signal, as a measure of total amount of DNA used in the amplification reaction.
For quantitation, normalised t(14;18) PCR signals are related to a single calibrator sample. The
method was demonstrated for monitoring disease activity in a follicular NHL patient using
peripheral blood and bone marrow samples. Quantitative data correlated with clinical data,
showing persistence of disease after allogeneic bone marrow transplantation (BMT) that
preceded clinical evidence of relapse. After a single infusion of donor lymphocytes, lymphoma
cell numbers decreased to undetectable levels 22 months later, which is compatible with the
clinically observed graft-versus-lymphoma effect.
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Introduction
Intensive treatment regimens like myelo-ablative therapy followed by allogeneic bone marrow
transplantation (BMT) is a promising new treatment modality for selected patients with non-
Hodgkin’s lymphoma (NHL) of low-grade malignancy [1,2]. Relapse of follicular lymphoma
following allogeneic BMT may be successfully treated with donor leukocyte infusions. The
chromosomal translocation t(14;18) is frequently found in follicular NHL patients. In this
translocation, the proto-oncogene bcl-2 is aberrantly coupled to the immunoglobulin heavy
chain gene. This translocation can be detected by sensitive polymerase chain reaction (PCR)-
based assay [3]. Detection of the t(14;18) in post-BMT patient samples has been correlated
with relapse [4-6]. However, t(14;18) positive cells are also detectable in patients during long-
term clinical remissions [7,8]. Quantitative over qualitative data may therefore more accurately
reflect disease activity. Quantitative PCR assays have been developed [9,10], but their useful-
ness is limited by the laborious nature of the experiments and the high risk for false positivity
due to contaminations.
A new type of PCR-based assay has recently become available which makes use of the 5’
nuclease activity of Taq polymerase [11,12], in association with real-time amplification using
the ABI/PRISM 7700 sequence detector (PE-Biosystems: figure 1A). This type of reaction
requires the application of a non-extendible dual-labelled internal probe, which is degraded by
the nuclease activity of Taq polymerase during specific amplification (figure 1B). This probe
contains a 5’ fluorogenic reporter group (e.g. FAM or TET) and an internal or 3’ fluorogenic
quencher group (TAMRA). Laser-induced excitation of intact probe results in fluorescent energy
transfer from the reporter group to the quencher group, and therefore no or low reporter group
emissions are measured early in reaction, i.e. base-line emissions. During specific amplification,
the increase in reporter group emissions is proportional to the amount of PCR product formed.
Sample positivity is defined at the cycle number at which emitted fluorescence exceeds the 10
times standard deviation of base-line emissions measured between cycle 3 to 10, and is called
the threshold cycle (Ct) (figure 1C). The Ct is proportional to the initial number of target
molecules [13,14], and is used for quantitative analysis. This type of PCR allows for large-scale
quantitative screening of patients blood and bone marrow samples with any amplifiable
disease-associated marker like the t(14;18) in follicular NHL. It may therefore more accurately
monitor disease activity and the efficacy of intensive treatment of the critically ill patient.
We developed a new real-time quantitative PCR assay for the detection of residual
t(14;18) positive lymphoma cells in blood and bone marrow samples of follicular NHL patients
during treatment. The technique was used to study the course of disease in a follicular NHL
patient. We were able to demonstrate on molecular level, persistence of disease after allogeneic
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Figure 1. (A) Schematic overview of the ABI/PRISM 7700 sequence detector. (B) Degradation of the
internal oligonucleotide by exonuclease activity of TAQ-polymerase during specific amplification. (C)
Sample positivity is defined at the cycle number at which emitted fluorescence exceeds the 10 times
standard deviation of base-line emissions, i.e. the threshold cycle (Ct).
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BMT despite a clinical complete remission. An increase in the number of lymphoma cells
preceded clinical relapse. Relapse was treated with a single infusion of donor leukocytes.
Hereafter, a decline in the number of lymphoma cells was measured by our assay, which is
compatible with the clinically observed graft-versus-lymphoma activity by donor leukocytes.
Materials and methods
Patient history
A 46-year old female patient received eight cycles of CVP (cyclophosphamide, vincristine,
prednisone) chemotherapy for an Ann-Arbor stage IVA follicular centroblastic-centrocytic NHL
of low-grade malignancy with generalised lymphadenopathy and involvement of bone marrow.
A complete remission was achieved. At the end of a one-year maintenance treatment with
interferon-alpha2a, a relapse was diagnosed in initially involved nodes. Histologic examination
revealed follicular NHL of persistent low-grade malignancy. Treatment with chlorambucil was
instituted without improvement. In November ’93 she entered our BMT program because of
progressive disease. After bulk-reducing treatment with three cycles of CHOP (cyclophospha-
mide, doxorubicin, vincristine and prednisone) a complete remission was documented. After
conditioning with an infusion of idarubicin, high-dose cyclophosphamide and total body
irradiation, BMT was performed with a T-cell depleted bone marrow graft of her HLA-A, B and
DR identical MLC-negative sister in February ’94. She did not develop graft-versus-host disease
(GVHD). In December ’95, 22 months after BMT, a relapse of NHL of persistent low-grade
malignancy was diagnosed in initially involved lymph nodes and bone marrow. The patient
was treated with a single infusion of donor leukocytes derived from her original bone marrow
donor. A total dose of 0.5x108 CD3 positive lymphocytes per kg body weight was given as
single treatment. Thereafter, a gradual response was observed into a clinical complete remission
nine months after DLI, now lasting for over one year. Remarkably, the patient did not develop
GVHD, except for a dry mouth perception one year after donor leukocyte infusion for a period
of two months.
The t(14;18) amplification reaction
Circulating lymphoma cells carrying the t(14;18) in patient samples were quantified by a real-
time analysis [13,14] using the 5’ nuclease assay (TaqmanTM) [15] and the ABI/Prism 7700
sequence detector (Perkin-Elmer, Fostercity, USA) [11,12]. One µg of DNA isolated from
peripheral blood and bone marrow samples or from Ficoll 1077 enriched mononuclear blood
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cell fractions was used as template. Each sample was amplified in triplicate in the presence of
30 pmol MBR-2 and JH-con oligonucleotides10, 4 pmol of dual-labelled fluorogenic MBR
internal probe 5’-(TET)-CAC AGA CCC ACC CAG AGC CC-(TAMRA)-p3’, 125 µM dATP,
dTTP, dCTP and dGTP, 1.25 U of AmpliTaqTM DNA polymerase (Perkin-Elmer) and 4 mM
MgCl2 in PE sample buffer in a total volume of 50 µl. Samples were heated for 10 minutes at
95oC and amplified for 50 cycles of 30 seconds at 95oC and 90 seconds at 60oC.
The ß-actin amplification reaction
The ß-actin amplification reaction was performed on 100 ng sample DNA, such as estimated
from optical density at 260 nm, in the presence of 30 pmol ß-actin forward and reverse
oligonucleotides, 4 pmol of dual-labelled fluorigenic ß-actin probe [11], 125 µM dATP, dTTP,
dCTP and dGTP, 1.25 U of AmpliTaqTM DNA polymerase (Perkin-Elmer) and 3.5 mM MgCl2 in
PE sample buffer in a total volume of 50 µl. Samples were heated for 10 minutes at 95oC and
amplified for 50 cycles of 15 seconds at 95oC and 60 seconds at 60oC.
Results
Normalisation of the t(14;18) PCR signal
To develop an accurate quantitative assay for measuring residual t(14;18) positive lymphoma
cells in patient samples, it is necessary to correct for variations in DNA amount and for poten-
tial PCR inhibiting factors in the sample. For this, the t(14;18) PCR signal, reflecting the
amount of lymphoma cells, was expressed as a function of the β-actin PCR signal, reflecting all
cells present in the sample. This normalisation is only allowed if the amplification efficiencies of
both reactions are equal. To determine amplification efficiencies, serial dilutions of t(14;18)
carrying cell line SU-DHL-6 DNA in dH2O, ranging from 1 µg to 2.5 pg of genomic DNA, were
specifically amplified for the t(14;18) breakpoint as well as the β-actin locus. Initial template
concentrations were related to Ct’s in order to construct standard curves (figure 2). The
difference in both Ct’s (∆Ct) for each dilution was constant over a dynamic template concentra-
tion range of 5 logs (1 µg to 10 pg). Therefore, the amplification efficiencies of both reactions
are equal. Since the Ct is proportional to the initial template concentration, the ∆Ct actually
relates the amount of lymphoma cells to the amount of DNA used in the amplification reaction.
Comparison of the normalised t(14;18) PCR signal to a calibrator sample
∆Ct values of patient samples are related to absolute amounts of initial template concentrations
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by using either of the two following methods. First, a serial dilution of a positive control
(t(14;18) carrying cell line SUDHL6) into negative DNA is used to establish the mathematical
relation between initial template concentration and ∆Ct. Patient sample positivity can deviate
from this mathematical relation [11,12]. Second, ∆Ct values of patient samples can be com-
pared to a single reference or calibrator sample [16] using the following equation:
X0p = X0r x eff-(∆Ctp-∆Ctr) ⇒ X0p = 1500 x eff-(∆∆Ct)
(X0p and X0r are the initial amount of t(14;18) per microgram of DNA in the patient
sample and calibrator sample respectively, and eff is the efficiency of amplification reaction)
The actual efficiency of amplification for both reactions can be calculated from the slope of the
standard curves (figure 2). We used the second method, and the calibrator sample used in our
assay was 1 µg of a 100-fold diluted genomic DNA from t(14;18) carrying cell line SU-DHL-6
into K562 DNA which equals 1500 copies of t(14;18) per microgram of DNA.
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Figure 2. Amplification efficiencies of t(14;18) and β-actin PCR’s. The threshold cycles for the amplifica-
tion of the t(14;18) (closed circles) and the β-actin locus (closed squares) are plotted against the log of
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Table 1. Variation in t(14;18) threshold cycle in independent experiments.
Template 500ng 100ng 10ng 1ng 0.1ng
n - 11 13 13 12
Mean Ct - 22.90 26.61 30.43 34.33
SD -   0.97   0.95   1.20   2.00
n = number of samples tested; Ct = threshold cycle; SD = standard deviation
Table 2. Variation in t(14;18) threshold cycle in a single experiment.
Template 500ng 100ng 10ng 1ng 0.1ng
n 10   8   8   8   8
Mean Ct 21.85 22.24 26.12 29.69 32.38
SD   0.16   0.17   0.28   0.28   0.30
n = number of samples tested; Ct = threshold cycle; SD = standard deviation
Validation of the real-time quantitative PCR assay
In order to validate our quantitative PCR for the detection and quantitation of residual t(14;18)
carrying cells in consecutive patient samples, we determined the variation in Ct’s for multiple
samples in a single t(14;18) amplification experiment as well as in independent amplification
experiments. For this, up to 13 samples of 4 to 5 serial dilutions of t(14;18) positive cell line
SU-DHL-6 DNA in dH2O over a 5 log range were used as template and amplified as described.
Dependent on the dilution used, the standard deviation of Ct’s in independent experiments, in
which the reagent mixtures had been independently prepared, could be as high as 2 cycles,
implying a maximum variation in results with a factor 24 (table 1).
However, the variation in Ct’s within a single experiment was low with a maximum
standard deviation of only 0.30 cycles (table 2). This implies a maximum variation in results of
only 1.23 fold within a single experiment. For this reason, reference samples are included in
each amplification experiment.
Quantitative t(14;18) analysis
In figure 3 the course of disease is depicted as well as the results of the quantitative t(14;18)
analysis of peripheral blood and bone marrow samples. After BMT a fairly stable number of
500 circulating t(14;18) carrying lymphoma cells per µg DNA were detected despite a clinical
complete remission status. Bone marrow samples remained t(14;18) positive as well. Levels of
lymphoma cells in bone marrow paralleled the levels of lymphoma cells in peripheral blood. At
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the time of clinical relapse, the number of circulating lymphoma cells had increased dramati-
cally to 10,000 per µg DNA. After donor leukocyte infusion, the number of t(14;18) positive
cells in the peripheral blood decreased steadily to undetectable levels 22 months later.
Discussion
A strong correlation was demonstrated between the clinical course of a follicular NHL patient,
experiencing a graft-versus-lymphoma effect of donor leukocyte infusion, and the results of the
quantitative analysis of lymphoma cells in consecutive blood and bone marrow samples.
Conventional qualitative PCR analysis of circulating t(14;18) carrying cells would have resulted
in persistent positivity after BMT until clinical relapse. Only by performing quantitative instead
of qualitative analysis of consecutive blood samples, could a gradual decrease of circulating
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lymphoma cells after the infusion of donor leukocytes be demonstrated, compatible with a
graft-versus-lymphoma effect. This anti-tumour effect was clearly insufficient in the period after
BMT until donor leukocyte infusion, since the number of circulating lymphoma cells remained
rather constant despite an apparent clinical remission. Our data are the more convincing since
we found completely comparable results in the peripheral blood after independent sampling
and sample handling procedures (total blood samples and 1077 Ficoll enriched mononuclear
blood cell fractions).
Previously, a correlation was reported between a graft-versus-lymphoma effect of alloge-
neic BMT and quantitative t(14;18) monitoring, based on a competitive PCR assay [17]. In
contrast to conventional PCR, the real-time quantitative assay makes use of the threshold cycle
for quantitation. The threshold cycle is proportional to initial template concentration since it is
established in the early exponential phase of the PCR in which no competition for available
components exists. The system is semi-automated and uses fluorescent labels that facilitate
detection. The method is highly reproducible and its variation is mainly due to pipetting errors.
The system is closed and avoids post-PCR sample handling, thus minimising the risk of
contamination. Compared to conventional quantitative PCR procedures the assay is fast; the
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Figure 4. Plate design for real-time quantitative PCR analysis.
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96 wells format allows high throughput of samples (figure 4). For the first time in PCR-based
molecular diagnostics, test characteristics like sensitivity, reproducibility, efficiency of different
PCR’s, and signal to noise ratios can easily be obtained and compared between different
laboratories. The method can be further improved by the use of an artificial construct for all
types of t(14;18) breakpoints as a calibrator, and by a double probe assay in which both the
t(14;18) and the ß-actin reactions are performed within one tube, and finally by the use of a
single reagent mixture to decrease the risk of false positivity due to contamination. Real-time
quantitative monitoring of residual disease is a promising new technique to establish the
molecular biological disease status in patients with follicular lymphoma, in addition to the
clinical disease status. In future studies this quantitative monitoring may prove to be useful in
evaluating efficacy of treatment of these patients.
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Abstract
Quantification of residual disease by real-time PCR will become a pivotal tool in the develop-
ment of patient-directed therapy. In recent years, various protocols to quantify minimal residual
disease in leukaemia or lymphoma patients have been developed. These assays assume that
PCR efficiencies are equal for all samples. Determining t(14;18) and albumen reaction
efficiencies for sixteen follicular lymphoma patient samples revealed higher efficiencies for
blood samples than for lymph node samples in general. However, within one sample both
reactions had equivalent efficiencies. Differences in amplification efficiencies between patient
samples (low efficiencies) and the calibrator in quantitative analyses result in the underestima-
tion of residual disease in patient samples whereby the weakest positive patient samples are at
highest error. Based upon these findings for patient samples, the efficiency compensation
control was developed. This control includes two reference reactions in a multiplex setting,
specific for the ß-actin and albumen housekeeping genes that are present in a constant ratio
within DNA templates. The difference in threshold cycle values for both reference reactions, i.e.
the ∆Ct2-value, is dependent on the amplification efficiency, and is used to compensate for
efficiency differences between patient samples and the calibrator. The ß-actin reference
reaction is also used to normalise for DNA input. Furthermore, the efficiency compensation
control facilitates identification of patient samples that are so contaminated with PCR inhibitory
compounds that different amplification reactions are affected to a different extent. Accurate
quantitation of residual disease in these samples is therefore impossible with the current
quantitative real-time PCR protocols. Identification and exclusion of these inadequate samples
will be of utmost importance in quantitative retrospective studies, but even more so, in future
molecular diagnostic analyses.
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Introduction
Disease associated chromosomal markers facilitate specific detection of malignant cells in
patient tissues and fluids, and have proved useful for diagnostic and prognostic purposes. By
means of the polymerase chain reaction (PCR), malignant cells can be detected to a sensitivity
limit of about a single malignant cell in a background of 105 to 106 normal cells [1]. Monitoring
the number of residual malignant cells during the course of disease may predict for early
relapse, preceding apparent clinical manifestation, and may verify the efficacy of treatment
regimens [2-4]. Monitoring by quantitative PCR (QPCR) may become a fundamental tool to
support patient directed treatment in future, at least for certain types of malignancies. Various
QPCR analyses based on competitive PCR strategies have been developed in the past [5-8].
However, the use of these assays is frequently hampered by a high risk for contamination and
the labour intensity of the technique. Real-time PCR [9,10] based on Taqman chemistry
[11,12] has innovated PCR technology, allowing faster analysis of patient samples in a closed
system, thereby lowering the risk of contamination. The use of an internal fluorescent probe
warrants the specificity of the reaction and allows for the determination of sample positivity
within the exponential phase of the reaction.
Various quantitative real-time PCR and RT-PCR protocols have recently been developed
for the detection of disease associated chromosomal translocations [13-16], or disease associ-
ated T-cell receptor or Ig gene rearrangements [17,18]. All protocols developed thus far are
based on the assumption that patient samples and calibration samples have equal efficiencies
during amplification. At least for the amplification of genomic DNA templates this assumption
may not be true, since many patient samples seem contaminated with PCR inhibiting com-
pounds. It is exactly for this reason that competitive PCR’s have been developed in the past [5-
8]. Factors like DNA fragmentation [19], residual RNA in DNA preparations [20], the presence
of PCR inhibiting compounds like residual anti-coagulant heparin [21] or proteinase K-digested
heme compounds like haemoglobin [22] or myoglobin [23] will negatively affect PCR effi-
ciency.
In this report, we demonstrate that the amplification efficiency for different DNA templates
isolated from whole blood or bone marrow samples is subject to extensive variation, leading to
underestimation of minimal residual disease or false negative result in quantitative PCR
analyses. We developed a general real-time PCR control, i.e. the efficiency compensation
control (ECC), to compensate for different efficiencies between patient samples. This approach
comprises the inclusion of two different reference reactions, one of which is carried out with
mutant primers. Both reference reactions have been developed to amplify with equivalent
efficiencies on the same template. The exact difference in the threshold cycle values (Ct)
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between both reference reactions (∆Ct2-value) is dependent on the amplification efficiencies.
This ∆Ct2-value can, therefore, be used to calculate the exact efficiencies of both reactions for
each sample in comparison to a calibrator sample, and therefore provides a way to compensate
for differences in efficiencies between patient samples and the calibrator in quantitative
analyses. In this way, accurate estimation of residual disease in patient samples becomes
possible, regardless of DNA quality or the presence of PCR inhibiting compounds.
Methods and Materials
Real-time PCR
During PCR amplification, the number of molecules that is synthesised (Xn) depends on the
number of template molecules present at the beginning of the reaction (X0), the reaction
efficiency (E) and the number of amplification cycles (n) (eq. 1) [24]. In real-time PCR, sample
positivity is defined as the cycle number at which emitted fluorescence exceeds the 10 times
standard deviation of base-line emissions, and is called the threshold cycle (Ct). The number of
molecules synthesised at the threshold cycle (XCt) is specific but constant (C) for each type of
reaction and may depend on reporter dye (6-carboxy-fluorescein (FAM) or 27-dimethyl-4,5-
dichloro-6-carboxy-fluorescein(JOE)).
Xn = X0 * (1+E)
n  ⇔ XCt = X0 * (1+E)
Ct  ⇔ X0 = C * (1+E)
-Ct     (1)
Table 1. Definition of symbols.
Xn number of molecules at cycle n
X0 initial number of molecules
E efficiency of amplification
n number of cycles
Ct threshold cycle
C (C1-C6) constant
XCt number of molecules at Ct
X0N normalisation of target molecules to reference molecules
∆Ct1 = Cttarget - Ctreference
∆∆Ct1 = ∆Ct1sample - ∆Ct1calibrator
∆Ct2 = Ctßact - CtAlb
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Normalisation
To correct for differences in DNA or RNA load between patient samples, the target PCR,
(t(14;18) in this report, is normalised to a reference PCR, ß-actin in this report, that is specific
for an endogenous housekeeping gene. The t(14;18) and the ß-actin reactions outlined in this
report have equivalent amplification efficiencies, allowing direct normalisation of the t(14;18)
PCR to the ß-actin PCR at the Ct-level (eq. 2; K. Livak, personal communication and Applied
Biosystems User Bulletin #2).
X0, target 
= X0 N =
 C1 * (1+E)
-Ct[target] 
⇔ when Etarget = Eref  ⇒ X0  N = C3 * (1+E)
-∆Ct1      (2)
  X0, ref   C2 * (1+E)
-Ct[ref]
PCR efficiency
The efficiency (E) of a reaction can be determined by a standard curve. Ct-values for serial
template dilutions in dH2O are related to the logarithm of the dilution factor, and the slope is a
measure for reaction efficiency (eq. 3; K. Livak, personal communication and Applied
Biosystems User Bulletin #2):
eff = E = 10 
-(    1     )
 - 1
 
 slope   (3)
Quantification using a single calibrator
For quantification, patient samples can be related to a single calibration sample, facilitating the
use of eq. 4 (i.e. the comparative Ct-method, K. Livak, personal communication and Applied
Biosystems User Bulletin #2). However, this method demands equivalent amplification
efficiencies between patient samples and the calibrator.
X0 N, sample 
= 
 C3* (1+Esample )
-∆Ct1S 
  ⇔
  X0 N, Cal      C2 * (1+ECal )
-∆Ct1C
when   ESample = ECal  ⇒  X0  N, Sample = X0 N , Cal * (1+E)
-∆∆Ct1
          (4)
whereby    ∆∆Ct1 = ∆Ct1S  -  ∆Ct1C
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The calibrator (X0N,Cal) used for the quantitation of circulating lymphoma cells during the
course of disease in follicular non-Hodgkin's lymphoma (NHL) patients is a 100-fold dilution of
t(14;18) positive cell line SUDHL6 DNA into a DNA pool obtained from four EBV-induced
lymphoblastoid B-cell lines, and equals 750 t(14;18) carrying lymphoma cells per 0.5 µg of
DNA (equivalent to 75.000 cells) [4,14].
The efficiency compensation control (ECC)
The ECC outlined in this report is used to compensate for varying PCR efficiencies between
patient samples and the calibrator. The ECC depends on two different reference reactions, i.e.
the multicopy ß-actin gene and the single copy albumen gene. Both reactions amplify with
equivalent efficiencies on identical DNA templates (see results), but provide different Ct-values.
The difference between both Ct-values, i.e. the ∆Ct2-value, is solely dependent on the actual
PCR efficiency for that template (eq. 5):
X0[βact] 
=
C4 * (1+E)
-Ct[βact] 
= C6 * (1+E)-∆Ct2 (5)
 X0[Alb] C4 * (1+E)
-Ct[Alb]
whereby    ∆Ct2 = Ct(βact) - Ct(Alb)
∆Ct2-values can be used to determine amplification efficiencies for patient samples relative to
the efficiency of the calibrator, providing a correction factor for different efficiencies between
patient samples and the calibrator (eq. 6):
(6)
This correction factor can be introduced into eq. 4, facilitating the quantification of patient
samples relative to a single calibrator with compensation for different efficiencies between
patient samples and the calibrator sample (eq. 7):
       
(7)
X0[βact] 
(sample)  =
X0[βact]
 (Cal) ⇒ C6*(1+ESample)
-∆Ct2S = C6*(1+ECal)
-∆Ct2C ⇒
X0[Alb] X0[Alb]
⇒  (1+ESample)
∆Ct2C
, when ESample = ECal  ⇒  ∆Ct2S = ∆Ct2C
∆Ct2S
X0 N, Sample =  X0 N, Cal *  (1+ECal)
 -{∆Ct2C * ∆∆Ct1}∆Ct2S
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DNA isolation
Patient whole blood sample DNA was isolated by a standard high-salt-lysis method as de-
scribed by Miller et al [25].
t(14;18) PCR analysis
Amplification reactions are performed in the ABI/Prism 7700 sequence detector (Applied
Biosystems, Fostercity, CA). Five hundred nanograms of patient sample DNA is amplified in
duplicate in the presence of 300 nmol/l oligonucleotides MBR-2 (5’-TCC CTT TGA CCT TGT
TTC TTG A-3’; bp 2816-3037 of GenEMBL database entry acc. 14745) and JH-con [1], 160
nmol/l of dual-labelled fluorogenic MBR internal probe 5’-(FAM)-CAC AGA CCC ACC CAG
AGC CC-(TAMRA)-p3’, 250 µmol/l dNTPs, 1.25 U of AmpliTaq DNA polymerase and 4 mmol/l
MgCl2 in Sample Buffer A (Applied Biosystems) in a volume of 50 µl. Samples are heated for
10 minutes at 95oC and amplified for 50 cycles of 15 seconds at 95oC and 60 seconds at
60oC.
The efficiency compensation control
Five hundred nanograms of patient sample DNA is amplified in duplicate in the presence of
100 nmol/l ß-actin forward and reverse primers [7], 100 nmol/l of dual-labelled fluorigenic ß-
actin probe [7], 300 nmol/l mutant albumen forward (5’-TGA AAC ATA CGT TCC CAA AGA
GCC T-3’) and reverse (5’-GAG AGG AAG AGT CTT TCA CAC GTA GA-3’) primers, 100
nmol/l of dual-labelled fluorigenic albumen probe (5’-(JOE)-TGC TGA AAC ATT CAC CTT
CCA TGC AGA-(TAMRA)-3’), 250 µmol/l dNTPs, 1.25 U of AmpliTaq DNA polymerase and 4
mmol/l MgCl2 in Sample Buffer A in a total volume of 50 µl. Amplification conditions are the
same as mentioned above.
Results
To study variation in amplification efficiencies among patient DNA samples, the efficiencies of
our t(14;18) and albumen PCR’s were first tested on cell line DNA. Genomic DNA from the
t(14;18) carrying cell line SUDHL6 was serially diluted in dH20 and amplified in duplicate to
construct t(14;18) and albumen standard curves for eight to ten independent experiments. R2
values of all curves exceeded 0.98, and reaction efficiencies were calculated from the slopes
(eq. 3). The average efficiencies for the t(14;18) reaction (n=11) and the albumen reaction
(n=8) were E=0.91±0.05 and E=0.93±0.04, respectively (table 2). We then determined the
efficiencies for both reactions on patient DNA samples that were isolated from lymph node
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biopsies or whole blood specimen (table 2). Lymph node DNA samples most likely seem to
contain higher contents of PCR inhibiting compounds resulting in lower amplification
efficiencies compared to patient whole blood DNA samples. Both reaction efficiencies for each
DNA sample compared, showed that a low efficiency for one reaction was accompanied by a
low efficiency for the other reaction. For lymph node DNA samples the average efficiencies for
the t(14;18) and albumen reactions are E=0.66 and E=0.72 respectively, but are E=0.94 and
E=0.94, respectively, for whole blood DNA samples. The average efficiency difference (∆E-
value) between both reactions is ∆E= 0.023 for lymph node DNA samples (n=3 pairs) and
∆E= -0.009 for whole blood DNA samples (n=8 pairs).
Based on these observed differences in reaction efficiencies between patient samples (table
2), we have developed the ‘efficiency compensation control (ECC)’. This control uses two
reference reactions that are specific for the ß-actin and the albumen housekeeping genes.
When testing both reaction efficiencies on serial B-cell line DNA pool dilutions (DNA pool from
Table 2. t(14;18) and albumen PCR efficiencies for follicular NHL patient lymph node and peripheral
blood DNA samples.
Patient Patient t(14;18) PCR product Et(14;18) EAlbumen ∆E
no. biopsy length (bp) ¥
SUDHL6 385 0.91±0.05 (n=11) 0.93±0.04 (n=8)   - 0.02
1 LN 312 0.75a 0.70e 0.05
2 LN 363 0.74a 0.72e 0.02
3 LN 350 0.59a 0.59e 0
4 LN 360* 0.67b/0.59a ND -
5 LN 267* 0.63b/0.58a ND -
6 LN 299 ND 0.95e -
7 LN 449 ND 0.65e -
mean 343 0.66 0.72 0.023
8 PB 398 0.97c 0.95f/0.91h 0.04
9 PB 367 1.03c 0.97f 0.06
10 PB 366 0.89c 1.0f/0.94h   - 0.08
11 PB 329 0.84c 0.85f   - 0.01
12 PB 313 1.05d 0.96g 0.09
13 PB 343 0.91d 0.99g   - 0.08
14 PB 520 0.91d 0.92g   - 0.01
15 PB 337 0.89d 0.97g   - 0.08
16 PB 336* ND 0.87g -
mean 368 0.94 0.94   - 0.009
LN = lymph node, PB = peripheral blood.
*larger PCR products are also formed due to priming of JHcon primer to downstream JH-gene segments.
¥ Product size was determined from the breakpoint sequence and confirmed by gel electrophoresis.
a-hSamples amplified within the same amplification reaction.
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four EBV-induced B-cell lines), both reactions performed with efficiencies of E=0.95 and
E=0.94 for the ß-actin and albumen reaction, respectively. ß-actin is a multicopy gene with
several pseudo-genes and albumen is a single copy gene, and are present in a constant ratio for
genomic DNA templates. Both PCR’s will therefore produce different Ct-values at identical
template concentrations (figure 1). For genomic DNA templates, the ∆Ct2-value between these
reactions (∆Ct2-value) is exclusively determined by the actual amplification efficiencies for both
reactions (figure 1), and is independent of initial DNA concentration. In the experiment as
described above, the ∆Ct2-value between the ß-actin reaction and the albumen reaction
remained constant over all serial B-cell line DNA pool dilutions (500 ng - 8 ng) and was
∆Ct2=3.86 ± 0.08. Samples that amplify with high reaction efficiencies will provide lower
∆Ct2-values in comparison to samples that are contaminated with PCR inhibiting compounds
and consequently amplify with lower reaction efficiencies (figure 1). This ∆Ct2-value can
therefore be used to compensate for efficiency differences between patient samples and the
calibrator in quantitative minimal residual disease studies. The target and reference PCR’s
should be performed on the same template dilution to exclude differences in reaction
efficiencies.
 
Relative 
fluorescence 
(∆Rn) 
Number of PCR Cycles 
threshold 
∆Ct at 
∆Ct at low 
∆Ct at high E < ∆Ct at low E 
Figure 1. Theoretical schematic illustration of ß-actin and albumen amplification curves at high and low
reaction efficiencies (E). The ß-actin (black curves) and albumen (grey curves) amplification curves and
Ct-values at high (solid lines) and low (stippled lines) reaction efficiencies for a hypothetical genomic DNA
template concentration. Low reaction efficiencies result in higher Ct-values for both reactions in a non-
linear relationship (eq. 1). DNA templates with higher efficiencies for both reactions will have lower
difference in Ct-values between both reference reactions (low ∆Ct2-values) than templates with lower
reaction efficiencies (high ∆Ct2-values).
∆Ct at high E
∆Ct at low E
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We then calculated the ∆Ct2-value that is theoretically needed between two reference
PCR’s in order to distinguish between efficiency differences as low as E = 0.05. This will of
course depend on the reproducibility of both Ct-values for the reference reactions. The stand-
ard deviations in Ct-values for both reference reactions performed on the serial B-cell line DNA
pool dilutions as described above ranged between 0.007 cycles for 0.5 µg DNA to 0.11 cycles
for the highest dilution (0.8 ng DNA). Assuming a SD in Ct-values of 0.11 cycles for both
reference reactions, the ∆Ct2-value between both reactions needs to be in the order of ten
cycles to distinguish between efficiency differences among DNA samples as low as ∆E = 0.05.
No combinations of multicopy gene PCR’s (ß-actin, 18S ribosomal DNA) versus single copy
gene PCR’s (albumen, RNAse-P) were identified that produced a sufficient ∆Ct2-value. As an
alternative, a mutant albumen primer pair was designed that amplified with an efficiency of E
= 0.96, compared to the ß-actin PCR (E = 0.95 as described above). The mutant albumen
primer pair produced Ct-values that were about 6 cycles higher Ct-values for each template
dilution in comparison to the wild-type albumen reaction. The ∆Ct2-values between the ß-actin
PCR and this mutant albumen PCR was about 9 cycles over all template dilutions tested. This
PCR combination may work for the Efficiency Compensation Control. To minimise variation in
Ct-values for both reactions, a multiplex PCR was developed. Using 100 nmol/l of ß-actin
primers and 300 nmol/l of mutant albumen primers, both reactions produced Ct-values of
19.98±0.10 and 30.06 ±0.03, respectively, in a multiplex setting, and Ct=19.25±0.01 and
27.62±0.04, respectively, in separate PCR’s.
The ECC was tested in a retrospective study on 47 selected blood and bone marrow DNA
samples obtained from 12 follicular NHL patients that had been isolated between 1990-1994
using the high-salt-lysis method [25]. Two of these samples had previously demonstrated
severe PCR inhibition as assessed by conventional PCR (not shown). PCR inhibition was not
due to DNA degradation as determined by gel electrophoresis (not shown). When performing
the ECC multiplex PCR, thirty-two samples produced reasonable Ct-values for both reference
PCR’s with ∆Ct2-values (range ∆Ct2 =8.19 - 9.88; mean ∆Ct2 = 9.04). Assuming an average
amplification efficiency of E = 0.94 for these samples (table 2), the efficiency for each sample
was then calculated based upon the ∆Ct2-value and ranged between E = 0.83 and E = 1.07
(eq. 6). Fifteen remaining patient samples (32%) produced ∆Ct2-values lower than ∆Ct2 =8.19
(∆Ct2 = -6.83 to ∆Ct2 = 7.82), and theoretically correspond to abnormal efficiencies of
E = 1.15 and higher. These samples may suffer from severe PCR inhibition that affects both
reference PCR’s to a different extent, and can therefore not be corrected for different
efficiencies using the ECC. Analysis of ∆Ct2-values from freshly isolated patient DNA samples
in a prospective study revealed that 2 out of 50 samples (4%) suffered from this same problem
(not shown).
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The ∆Ct2-based efficiencies were compared to efficiencies that were calculated from standard
curves. Four samples with high ∆Ct2-values (low efficiency) and four with low ∆Ct2-values
(high efficiency) were selected to construct standard curves. For seven out of eight samples, the
ECC determined efficiencies match the efficiencies as determined from the standard curves of
the t(14;18) and albumen PCR (table 3). For five samples, the ECC based efficiencies fall
within the SD of the efficiencies that were derived from standard curves.
Discussion
In quantitative PCR studies monitoring for minimal residual disease, patient samples are
compared to a golden standard that either consists of a well-defined calibrator sample (i.e. the
comparative Ct-method) or consists of a calibrator serial dilution. All real-time quantitative PCR
studies performed thus far are based on the assumption that PCR efficiencies are the same for
patient samples and the calibrator. However, many factors affect PCR efficiency and conse-
quently the outcome of quantitative PCR analyses. It is commonly believed that amplicon size
plays an important role in this matter, as well as contaminating factors in the patient sample
that will inhibit the amplification reaction and will therefore delay reaction efficiency. A few of
these PCR inhibiting factors have been characterised that interfere with quantitative PCR
analyses, especially within the haemato-oncology field [19-23].
Testing the efficiencies for the t(14;18) target and albumen reference PCR for various
patient DNA samples, efficiencies for both reactions varied between different patient samples
probably due to contaminating PCR inhibiting compounds. PCR efficiency was not affected by
Table 3. Comparison of reaction efficiency as determined from the Efficiency Compensation Control
(EECC) and as determined from the slope of standard curves (ESC).
Patient no. ∆Ct2 EECC ESC
17a 9.88 0.83 0.92  ± 0.01
17b 9.47 0.88 0.84  ± 0.05
18a 9.41 0.89 0.89  ± 0.01
19a 9.47 0.88 0.92  ± 0.01
1a 8.32 1.05 1.04  ± 0.02
4a 8.51 1.02 1.00  ± 0.05
20a 8.66 1.0 1.06  ± 0.08
21a 8.56 1.01 0.96  ± 0.04
Patient sample DNA isolated from peripheral blood samplesa or bone marrow aspiratesb. The experimen-
tally determined efficiency (ESC) is the average efficiency for the β-actin and the mutant albumen reaction
as calculated from the slope of the standard curves.
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amplicon size (table 2), at least for amplicons ranging between 89 and 520 bp, nor was it due
to DNA degradation. DNA templates isolated from patient lymph node biopsies amplify with
lower efficiencies in comparison to patient whole blood DNA samples (table 2). Most impor-
tantly, for each DNA sample the efficiencies for both PCR’s were equivalent, indicating that a
low t(14;18) reaction efficiency for a DNA template is accompanied by a similar low efficiency
for the albumen reaction for that same template. This indicates that PCR inhibiting factors
affect different reactions performed on the same template to a similar extent. For all t(14;18)
and albumen standard curves, the deviations of Ct-values for all template dilutions relative to
the regression curve were equivalent, and no evidence was found for increasing deviations at
higher template dilutions as should be expected in case of dilutable PCR inhibition (all R2
values exceeded 0.98 but in general were in the order of 0.995). PCR inhibition for the
samples evaluated in this study was non-dilutable, and is presumably caused by compounds
that tightly bind to the DNA like haemoglobin degradation compounds.
Our results show that quantitative studies tend to suffer from efficiency differences between
samples, leading to inaccurate results. For instance, lower reaction efficiencies for patient
samples resulting in higher Ct-values will lead to underestimation of residual disease content.
This especially affects patient samples with low residual malignant cell numbers. Normalisation
of the target PCR (the t(14;18) reaction in this report) to a reference PCR, usually specific for
an endogenous housekeeping gene, will only partially compensate for this problem since the
number of reference gene copies is always relatively high in comparison to the number of
target copies reflecting the amount of malignant cells. The efficiency compensation control was
developed to compensate for sample specific efficiency variation in comparison to a calibrator
(equation 7), and consists of a multiplex PCR for two endogenous house keeping genes, i.e. ß-
actin and albumen, that are present in a constant ratio in DNA templates but that produce
different Ct-values (∆Ct2) for identical template. Both reactions performed with equivalent
efficiencies on serial template dilutions, and it is reasonable to assume that both ECC reference
reactions will be equally affected by contaminating PCR inhibiting substances as is the case for
the t(14;18) and wild-type albumen PCR. The ∆Ct2-value is therefore independent of initial
template concentration, but depends on the exact amplification efficiencies (equation 6). The
ECC can theoretically distinguish between patient samples that differ in amplification
efficiencies as low as E = 0.05. Disease associated chromosomal aneuploidy involving the ß-
actin or albumen genes may affect results obtained by the ECC. This is unlikely for follicular
NHL blood or bone marrow samples since the total number of circulating t(14;18) positive
lymphoma cells during the course of disease is in general below five percent of total mononu-
clear cells [3,4,8]. However, for leukaemias with a high tumour cell percentage in blood and
bone marrow samples during apparent disease in contrast to clinical remission phases, this
could be a problem.
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Patient DNA templates that had been stored for several years produced abnormal ECC
∆Ct2-values for 32% of the samples compared to 4% of freshly isolated patient DNA samples.
For these samples, the ECC will not be useful to correct for efficiency differences in comparison
to a calibrator sample. These samples probably contain so many PCR inhibiting compounds
that different PCR’s are affected to a different extent. Quantitation of residual disease in these
samples will therefore not be possible. The ECC seems very useful in identifying such patient
samples in quantitative analyses.
In conclusion, the ECC serves three purposes: first, the β-actin Ct-value for each sample is
used to normalise for different DNA input. Second, the ECC ∆Ct2-value is used to compensate
for efficiency difference in comparison to the calibrator. Third, the ECC identifies patient DNA
templates that may not be quantifiable for minimal residual disease content due to unequal
inhibition of the various amplification reactions. Since the ECC uses two reference PCR’s that
are specific for endogenous house keeping genes, it may be applicable as a general control in
real-time quantitative studies using genomic DNA templates. In our opinion, the ECC approach
is a powerful control for Taqman-based analyses that can be performed in the ABI PRISM 7700
system (Applied Biosystems) but needs further evaluation in other real-time PCR systems. For
probe designs, other fluorescent reporter groups can be used, but FAM in combination with
JOE or VIC proved to be a useful combination in a multiplex setting. Hydrolysing probes may
be replaced by molecular beacons or scorpion primers [26].
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Graft-versus-lymphoma effect of donor leukocyte
infusion demonstrated by real-time
quantitative PCR analysis of t(14;18)
Background
Patients with relapsed follicular non-Hodgkin’s lymphoma (NHL) after allogeneic bone marrow
transplantation (BMT) may respond to infusion of leukocytes derived from the original marrow
donor. In follicular lymphoma the characteristic chromosomal translocation t(14;18) can be
used to monitor disease activity by performing polymerase chain reaction (PCR) analysis. We
used a new real-time quantitative PCR to substantiate the graft-versus-lymphoma effect of
donor leukocyte infusion, given for relapsed follicular NHL after BMT.
Methods
Cells carrying t(14;18) were quantified by real-time PCR analysis [1] using Taq  polymerase
and an internal fluorogenic probe in the ABI/Prism 7700 sequence detector. During specific
amplification the hybridised probe is degraded by Taq polymerase, resulting in laser-induced
fluorescence emission, reflecting the amount of PCR product formed. The cycle number at
which fluorescence equals the 10 times standard deviation of background fluorescence is called
threshold cycle (Ct), and is proportional to the initial template concentration [2].
To correct for variations in DNA amount and PCR inhibiting factors the t(14;18) Ct was
normalised to the ß-actin Ct, which was permitted as both PCR’s had identical amplification
efficiencies (data not shown). To quantify t(14;18) carrying cells the normalised t(14;18) Ct of
patient samples were compared to that of a calibrator sample with a known number of t(14;18)
per µg DNA. We validated the assay by determining the variation in Ct’s for multiple samples
within a single experiment, which was low (range 0.16-0.30, implying a maximum variation in
results of only 1.23 fold).
Results
In November ’93 a 48-year old female patient showed progression of a low-grade follicle centre
cell NHL after two treatment regimens. Prior to BMT, tumour-bulk reducing therapy with three
cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) resulted in a
complete remission. After conditioning with idarubicin, cyclophosphamide and total body
irradiation, BMT was performed with a T-cell depleted graft of her HLA-identical sister. No
graft-versus-host disease (GVHD) developed. Twenty-two months later a relapse of persistent
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low-grade malignancy was diagnosed in initially involved lymph nodes and bone marrow.
Single treatment with infusion of leukocytes of the original marrow donor gradually resulted in
a complete remission, including a lymphoma-negative bone marrow, which is now lasting for
over one year. Temporary complaints of a dry mouth, presumed to represent limited chronic
GVHD, were left untreated.
Figure 1 shows clinical and molecular observations over time. After BMT lymphoma cells
persisted in blood and bone marrow while the patient was in clinical complete remission. The
number of lymphoma cells markedly increased before clinical relapse and subsequently
decreased to undetectable levels after donor leukocyte infusion.
Figure 1. Calculated amount of t(14;18) carrying cells in blood and bone marrow samples related to
clinical remission status in time.
Abbreviations: BMT = bone marrow transplantation; DLI = donor leukocyte infusion; cGVHD = chronic
graft-versus-host disease; CR = complete remission; PR = partial remission; PB = peripheral total blood
samples; 1077 = 1077 Ficoll enriched peripheral mononuclear blood cell fractions; BM = bone marrow;
‘0’ indicates below the detection level of the PCR.
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Discussion
In this patient with relapsed follicular NHL after BMT, infusion of donor leukocytes had an
unequivocal anti-lymphoma effect. Up to now evidence of graft-versus-lymphoma in low grade
NHL is only circumstantial: remissions can be induced by BMT [3,4], cessation of immunosup-
pression at relapse after BMT may induce response [5], and finally, another patient from our
department responded to donor leukocyte infusion [4]. The gradual decrease of lymphoma
cells in blood and bone marrow, as shown by the new real-time quantitative PCR, for the first
time substantiates this graft-versus-lymphoma effect. The quantitative rather than a merely
qualitative monitoring of lymphoma cells reflected disease activity in our patient and elegantly
showed the more pronounced graft-versus-lymphoma effect of the donor leukocyte infusion as
compared to the BMT itself.
Real-time quantitative PCR analysis of t(14;18) is a promising new technique to establish
molecular disease status in follicular NHL, and may prove useful in evaluating treatment
efficacy and prognosis.
Acknowledgements
We thank C. Noordanus and K. Livak (Perkin-Elmer) for technical and theoretical support, E. Tönnissen
and L. van de Locht (Central Hematology Laboratory, University Medical Centre Nijmegen) for performing
PCR analysis and technical assistance and J. Bogman, MD, PhD (Dept Pathology, University Medical
Centre Nijmegen) for critically revising histological material.
References
1. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. In: Genome meth-
ods. Genome research. Cold Spring Harbor Laboratory Press. ISSN 1054-9803/96. 1996:986-94.
2. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of
DNA amplification reactions. Biotechnology 1993;11:1026-30.
3. Van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for
refractory and recurrent low-grade lymphoma: the case for aggressive management.
J Clin Oncol 1995;13:1096-102.
4. Mandigers CMPW, Raemaekers JMM, Schattenberg AVMB, et al. Allogeneic bone marrow
transplantation with T-cell depleted marrow grafts for patients with poor-risk relapsed low-
grade non-Hodgkin’s lymphoma. Br J Haematol 1998;100:198-206.
5. Van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after
allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
Bone Marrow Transplant 1997;19:977-82.
Stem cell transplantation
65
C.M.P.W. Mandigers, A.V.M.B. Schattenberg, J.M.M. Raemaekers
C H A P T E R
6
Stem cell transplantation in indolent
non-Hodgkin’s lymphoma
adapted from:
Stamceltransplantatie bij patiënten met een non-Hodgkin lymfoom van lage maligniteitsgraad.
Nederlands Tijdschrift voor Geneeskunde 2000;144:2045-2048 (review)
66
Chapter 6
Stem cell transplantation in indolent
non-Hodgkin’s lymphoma
Summary
Patients with an indolent non-Hodgkin’s lymphoma have been considered to be incurable for
decades. Several conventional therapies have resulted in an improved disease-free survival but
not in a prolonged overall survival. Intensified treatment of relapsed patients with myelo-
ablative conditioning followed by autologous or allogeneic stem cell transplantation (SCT) is
being applied more and more. In both forms of SCT the anti-tumour effect of the high-dose
chemo- (and radio-) therapy is used; allogeneic SCT has an additional so-called graft-versus-
lymphoma effect. Therefore allogeneic SCT appears to be a promising and potentially curative
treatment for this patient group, despite complications as graft-versus-host disease and higher
treatment-related mortality. Early in the course of a low-grade NHL, especially at first relapse,
an allogeneic SCT should at least be considered for a patient having an HLA-compatible stem
cell donor.
Introduction
Patients with an indolent non-Hodgkin’s lymphoma (NHL) have a characteristic course of
disease. At presentation there is in general already a generalised lymphadenopathy and bone
marrow involvement. Conventional chemotherapy usually results in a remission, although
seldom completely, and relapses are common. After a period of several relapses the lymphoma
is eventually becoming therapy-resistant, after dedifferentiation to a more aggressively growing
type, resulting in the death of the patient. The median survival has not been improved during
the last decades, and lasts for 8-10 years [1], despite new therapies as interferon-alpha, purine-
analogous and monoclonal antibodies [2].
It is not surprising that in this chemo- and radiotherapy-sensitive tumour dose escalation
has been studied. Now experience with high-dose treatment, followed by infusion of the
patient’s own (autologous) stem cells, but particularly stem cells of related or even unrelated
donors (allogeneic stem cell transplantation), has increased, warranting special attention to
these intensive treatments. In this article we only discuss two types of indolent NHL, the
follicular and the small lymphocytic type [3], as experience with stem cell transplantation (SCT)
in especially these types is present.
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Autologous stem cell transplantation
Using conventional chemotherapy in patients with indolent lymphoma treatment of each next
relapse results in an ever shorter duration of remission [4]. Remissions after autologous SCT for
relapsed disease have been reported to last for median 2-5 years [5-11], and seem to last
longer that that after the preceding conventional chemotherapy [12]. Considering the pro-
longed progression-free survival after autologous SCT, an increased duration of the overall
survival was expected too. Unfortunately, such an improvement of the prognosis of this patient
group has not been demonstrated yet. The only randomised study comparing autologous SCT
with conventional chemotherapy in relapsed indolent NHL, cannot be analysed, as it had to be
stopped early due to an insufficient number of patients [10]. The role of autologous SCT in
first-line treatment of patients with follicular NHL was tried to determine in a study of both the
Lymphoma Group of the EORTC (European Organisation for Research and Treatment of
Cancer) and the HOVON (Haematologie Oncologie Volwassenen Nederland). Unfortunately,
this study also ended early for a too small number of patients. A similar German study is still
ongoing. Considering current literature we would like to conclude that, although not proven in
randomised studies, high-dose chemo- and radiotherapy supported by infusion of autologous
stem cells can indeed induce an disease- and treatment-free period for years, but does not
result in a better overall survival.
It could be that relapses after autologous SCT are caused by re-infusion of malignant
lymphoma cells in the stem cell graft. As bone marrow involvement is common in indolent
NHL, it is seldom possible to harvest pure stem cells without contaminating lymphoma cells. It
has been reported that the risk of relapse after autologous SCT can be decreased by purging
the graft with monoclonal antibodies to residual malignant lymphoma cells [9]. However,
others could not confirm this finding [7,10,11].
Concern is growing about patients developing a secondary myelodysplastic syndrome
(MDS) after autologous SCT. The cumulative risk for a secondary MDS 10 years after autolo-
gous SCT rises to 7-15% [13,14].
In the light of the limitations of autologous transplantation mentioned above, the alloge-
neic SCT seems to be an attractive alternative. Here, a pure graft without contaminating NHL
cells is used, derived from a donor. Furthermore, the ‘graft-versus-lymphoma’ effect, an anti-
tumour effect from the donor lymphocytes against residual lymphoma cells, can improve the
prognosis.
Allogeneic stem cell transplantation
In 1995 the first results of allogeneic stem cell transplantation in 10 patients with relapsed
indolent NHL were described [15]. Eight of 10 patients had a lymphoma that was not sensitive
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any more to conventional chemotherapy. Stem cell grafts had been derived from HLA-
compatible related donors, and had been infused to the patients without manipulation. After a
median follow-up of 27 months no relapses had occurred and 8/10 patients were in complete
remission. Two patients had died from treatment-related causes.
In 1998 we reported the results of allogeneic SCT in 15 patients of the University Medical
Centre Nijmegen [16]. Up to now 26 patients have been treated in this way. All were high-risk
patients since their last remission, induced by conventional chemotherapy, lasted no longer
than 1,5 years [4]. To be eligible for allogeneic SCT the patients’ NHL had to respond to
conventional treatment. To decrease the risk of graft-versus-host disease (GVHD) 98% of T-
lymphocytes were depleted from the stem cell grafts. In 24/26 patients the donor was an HLA-
compatible sibling, and two patients received a graft derived from an unrelated donor. The
median age at SCT was 47 years (range 30-60). After a median follow-up of 41 months (range
1-113) 18/26 patients are in remission. Six patients have died within two years after allogeneic
SCT due to toxicity of treatment, and two from other causes, i.e. sepsis and squamous cell
carcinoma of the lung. The actuarial survival is 64% (95% confidence interval 44-84%) four
years after SCT (figure 1). In three patients the NHL relapsed after allogeneic SCT, resulting in
an actuarial relapse rate of 24% (95% confidence interval 0-48%) (figure 2). In all three again a
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Figure 1: Survival of 26 patients with an indolent non-Hodgkin’s lymphoma, treated with an allogeneic
stem cell transplantation in the University Medical Centre Nijmegen (t= end of follow-up in individual
patients)
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complete remission was induced by infusion of lymphocytes derived from the original stem cell
donor.
Survival of patients with an indolent lymphoma after allogeneic SCT is impaired predomi-
nantly by treatment-related mortality, usually due to acute or chronic graft-versus-host disease
and less frequently due to relapse after transplantation. Other authors too report low relapse
rates after allogeneic SCT [17,18]. This argues strongly for a reaction of the donor immune
apparatus directed against the residual NHL cells, the graft-versus-lymphoma effect. In support
of this theory is the response to infusion of donor lymphocytes, without concurrent treatment,
in patients with relapsed lymphoma after allogeneic SCT.
In a patient with relapsed follicular NHL after allogeneic transplantation we monitored
disease activity in the peripheral blood and the bone marrow by molecular biological
quantitation of tumour cells, characterised by the chromosomal translocation t(14;18). After
conventional chemotherapy as well as after allogeneic SCT t(14;18) positive lymphocytes
persisted in the peripheral blood. Just before clinical evidence of relapse the number of
circulating t(14;18) positive cells increased. After infusion of donor lymphocytes the number of
tumour cells in the peripheral blood and bone marrow gradually decreased to undetectable
levels, while clinically too a gradual response to a complete remission occurred [19]. At present,
Figure 2: Relapse in 26 patients with an indolent non-Hodgkin’s lymphoma, treated with an allogeneic
stem cell transplantation in the University Medical Centre Nijmegen (t= end of follow-up in individual
patients)
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over four years later, this patient is still in remission both clinically and molecularly. This shows
that in relapsed follicular NHL after allogeneic SCT curation can be achieved as yet by admin-
istration of lymphocytes derived from the original stem cell donor.
However that allogeneic SCT may be promising for patients with an indolent NHL, there is
a considerable risk at complications of this treatment, also due to the relatively high age of this
patient group. First, mortality rates within two year after SCT rise to 20-40%. Secondly, there is
a high incidence of moderate or serious graft-versus-host disease. Even using a stem cell graft
depleted of the majority of lymphocytes, half of patients develop chronic GVHD. This makes
long-term immunosuppressive therapy necessary, with the associated risks. Table 1 summarises
the results of studies on allogeneic stem cell transplantation in indolent NHL.
It will be clear that only a part of patients with an indolent lymphoma is eligible for an
allogeneic SCT. In general, an age above 60 years is a contra-indication because of the
increased risk of serious complications. Therefore it is studied whether less intensive condition-
ing regimens before allogeneic SCT lead to a lower transplant-related mortality. Here, it is
assumed that complete ablation of the bone marrow is not necessary to achieve a graft-versus-
lymphoma effect. Only one in three to four patients in fact has a HLA-compatible related
donor. The number of voluntary donors in the world wide donor bank is indeed increasing, but
still a transplantation with stem cells of an unrelated donor is associated with an increased risk
at complications, especially graft-versus-host disease. That’s why in general, such SCT are used
in patients younger than 50 years.
Table 1. Summary of allogeneic stem cell transplantation (SCT) in indolent non-Hodgkin’s lymphoma
Van Besien15 Van Besien18 Verdonck17 Update experience
Univ. Medical Centre
Nijmegen
number of patients 10 113 15 26
chemosensitive
disease at SCT 2/10 66/105 8/15 23/25
median age (range)
in years at SCT 36 (23-45) 38 (15-61) 44 (31-55) 47 (30-60)
median follow-up
(range) in months 27 (11-62) 25 (4-95) 25 (4-66) 41 (1-113)
continuous complete
remission 8/10 - 11/15 15/26
relapse 0/10 - 0/15 3/26
treatment related
mortality 2/10 45/113 4/15 6/26
overall survival at 5 years 80% at 3 years 49% at 3 years 70% at 4 years 64%
(95% confidence interval) (55-100%) (39-60%) (38-87%) (44-84)
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Considering the toxicity of an allogeneic SCT, until now patients are selected whose NHL
are shortly or not at all responding to conventional chemotherapy. It may be that performing
an allogeneic SCT earlier in the course of disease leads to fewer complications, but we can only
speculate on this.
Discussing an allogeneic SCT with patients with indolent lymphoma is difficult. It is
proposed to switch from a relatively mild, conventional treatment, directed to controlling the
disease as long as possible, to a very intense treatment, directed to cure the patient but poten-
tially inducing his death. Only after giving serious consideration to the pro’s and cons of an
allogeneic stem cell transplantation, this treatment can be chosen.
Conclusion
Allogeneic stem cell transplantation is the most important new treatment modality for a selected
group of patients with an indolent non-Hodgkin’s lymphoma. For the first time, cure is placed
in perspective now. A switch in thinking about indolent NHL is necessary for both the doctor
and the patient. Keeping in mind the considerable toxicity we recommend to consider an
allogeneic SCT in every patient, younger than 60 years, with an indolent NHL, shortly or not
responding to conventional therapy. Future studies will have to determine whether or not
toxicity is less by performing the SCT earlier in the course of disease, or by decreasing the
intensity of the conditioning before transplantation.
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Abstract
Purpose: Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases
after allogeneic stem cell transplantation (SCT).
Patients and methods: We treated seven patients with DLI for indolent non-Hodgkin’s
lymphoma (NHL) relapsed after SCT. In available blood and bone marrow samples lymphoma
cells were analysed by real-time quantitative polymerase chain reaction of t(14;18) positive
cells in follicular NHL, and by immunophenotyping in small lymphocytic NHL.
Results: Before DLI three patients were treated with chemo- and/or radiotherapy, and one
patient was given rituximab. Evaluable responses to pre-DLI therapy were stable disease in 1
and partial remission in 2 patients. DLI consisted of a median of 1.0 (range 0.5-1.0) x108
CD3+ cells per kg body weight. The relapsed lymphomas gradually responded to DLI to a
complete remission (n=4) and to a partial remission (n=3). In three cases consecutive blood
and/or bone marrow samples had been taken before and after DLI. In all three, clinical
responses could be substantiated by molecular or immunophenotypic analysis of lymphoma
cells. Five patients are alive and well; their responses to DLI are lasting for a median of 30
(range 5-70) months. Two patients died 2 and 17 months after DLI of Aspergillus fumigatus
pneumonia and liver failure of unknown cause, respectively. After DLI acute GVHD occurred
in three patients, classified as grade 2, whereas only limited chronic GVHD was seen (n=5).
Conclusion: DLI is effective for treatment of indolent lymphoma relapsing after SCT.
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Introduction
Myeloablative therapy followed by allogeneic stem cell transplantation (SCT) has emerged as a
promising treatment modality for selected patients with indolent types of non-Hodgkin’s
lymphoma (NHL). Response rates of 50-70% and relapse percentages of about 15 have been
reported in series of predominantly heavily pretreated patients [1-3]. As similar conditioning
regimens followed by autologous stem cell rescue result in comparable response, but higher
relapse rates [1,4,5], a graft-versus-lymphoma effect is assumed to be involved in allogeneic
SCT, as already suggested a decade ago [6]. In case of relapsed haematological disease after
allogeneic SCT remission can still be induced by shifting the balance between patient and
donor immuno-reactive cells in favour of the donor, either by diminishing the patient’s immu-
nosuppressive medication [7]. or by infusion of lymphocytes derived from the original stem cell
donor [8-12]. Especially in relapsed chronic myeloid leukaemia after allogeneic transplantation
these donor lymphocyte infusions (DLI) are effective, whereas in relapsed acute leukaemia
responses to DLI are rather disappointing.
Earlier we described a patient with relapsed follicular NHL after allogeneic SCT, in whom
the clinically observed graft-versus-lymphoma effect of DLI was substantiated by molecular
analysis of circulating cells carrying the characteristic chromosomal translocation t(4;18) [13].
Here, we describe seven patients treated with DLI for indolent lymphoma relapsed after
allogeneic SCT. The observed responses are illustrated with available molecular and
immunophenotypic data.
Patients and methods
Patients
Since 1989 in the University Medical Centres Nijmegen and Utrecht 50 patients have been
treated with myeloablative therapy and T-cell depleted allogeneic stem cell transplantation for
relapsed indolent lymphoma. Seven of them received DLI for the first relapse after SCT.
Donors were HLA-identical siblings. Grafts had been partially depleted of T-cells by
counterflow centrifugation [14] or SBA/E-rosetting [15] respectively. Characteristics of the
seven patients are given in table 1. Clinical, laboratory, radiological, and pathological data were
collected from the medical records. In case of lymphoma relapses post-SCT at localisations with
potential short-term threatening complications chemo- and/or radiotherapy was administered
prior to DLI. In the University Medical Centre Nijmegen patients were treated with one DLI,
consisting of 0.5 (range 0.5-0.7) x108 CD3+ cells per kg body weight. In the University
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Medical Centre Utrecht dose-escalated DLI was given, i.e. in case of failure in absence of graft-
versus-host disease (GVHD) of a first DLI, consisting of 1.0x107 CD3+ cells per kg, a second
DLI was given consisting of 1.0x108 CD3+ cells per kg. GVHD was staged according to
literature [16,17]. Follow-up ended at December 1rst, 2001.
Methods
In available bone marrow and blood samples lymphoma cells were analysed by real-time
quantitative polymerase chain reaction (PCR) of t(14;18) positive cells in follicular NHL
[18,19], and by immunophenotyping in small lymphocytic NHL. The sensitivity of the PCR is
detecting a single lymphoma cell in 75.000 normal cells.
Table 1. Patient characteristics (n=7) concerning allogeneic stem cell transplantation.
n median (range)
sexe male 3
female 4
age at SCT (years) 48 (32-56)
original histology follicular NHL 5
small lymphocytic NHL 2
Ann Arbor stage at diagnosis II 1
III 1
IV 5
number of previous treatment regimes 2 (1-4)
debulking before SCT anthracycline-based chemotherapy 6
fludarabine 1
chemosensitive to debulking 6
donor HLA-identical sibling 7
conditioning cyclophosphamide + TBI 4
idarubicin+cyclophosphamide+TBI 3
response to SCT complete remission 7
acute GVHD after SCT none 4
grade 1 3
chronic GVHD after SCT none 3
limited 4
Abbreviations: n = number, TBI = total body irradiation
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Results
Clinical data
Seven consecutive patients received therapeutic donor lymphocyte infusion after SCT for
relapsed indolent lymphoma. After the previous SCT neither acute GVHD ≥ grade 2 nor
extensive chronic GVHD occurred. Relapses were diagnosed after a median of 25 (range 12-
73) months after SCT. All patients presented with relapsing lymphoma at previously involved
lymph node sites. Furthermore, six patients had lymphoma involvement of the bone marrow.
Patient characteristics concerning the DLI are shown in table 2. DLI was given without any
pre-treatment in 3/7 patients. Prior to DLI, two patients were treated with anthracycline-
containing combination chemotherapy, preceded by radiotherapy in one, to induce rapid
response for complicating ischaemic colitis and osteolytic femoral lesion, respectively. Another
patient received anti-CD20 (rituximab) before DLI for clinically rapidly progressive, but
histologically still indolent lymphoma. Finally, one patient was treated with corticosteroids and
cyclophosphamide prior to DLI, as the relapsed indolent NHL concurred with polyneuropathy.
Response to pre-DLI therapy occurred in two patients, both achieved a partial remission.
The responses to DLI were complete remissions (n=4) and partial remissions (n=3). No
relapses have been observed after DLI. Responses of the living patients are lasting for a median
of 30 (5-70) months. Two patients have died up to now. The first patient died 2 months after
Table 2. Patient characteristics (n=7) concerning donor lymphocyte infusion.
n median (range)
therapy before DLI chemotherapy 2
chemotherapy and radiotherapy 1
rituximab 1
response to pre-DLI treatment not evaluable 1
stable disease 1
partial remission 2
CD3+ cells/kg infused (x10.8) 1.0 (0.5-1.0)
response to DLI complete remission 4
partial remission 3
acute GVHD after DLI none 4
grade 2 3
chronic GVHD after DLI limited 5
not evaluable# 2
deaths 2
relapse after DLI in surviving patients 0/5
PFS after DLI of living patients (months) 30 (5-70)
Abbreviations: n = number, # = chronic GVHD was not evaluable in two patients due to early death, PFS
= progression-free survival
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DLI of an Aspergillus fumigatus pneumonia, while receiving corticosteroids for acute GVHD
grade 2. The second patient died 17 months after DLI of liver failure of unknown cause, as
diagnostic procedures had been refused. After DLI three patients developed acute GVHD
grade 2, the remaining four patients had no acute GVHD. Chronic GVHD occurred in five
patients, all had only limited disease.
Molecular and immunophenotypic data
Figures 1 and 2 show the results of molecular monitoring of circulating follicular lymphoma
cells by real-time quantitative PCR analysis of t(14;18) positive cells in available bone marrow
and peripheral blood samples in two patients.
Molecular data of the first patient (figure 1) have in part been published previously [13].
Figure 1. clinical and molecular data (analysed in whole blood and bone marrow samples) of a patient
with follicular NHL, before and after SCT and subsequent DLI
Abbreviations: # t(14;18) / 75.000 cells = number of t(14;18) positive cells per 75.000 cells (0 means
‘below detection level’); CVP = cyclophosphamide, vincristine, prednisone; IFN = interferon-alpha; chl =
chlorambucil; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; SCT = allogeneic stem
cell transplantation; DLI = donor lymphocyte infusion; CR = complete remission; PD = progressive
disease; PR = partial remission
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She presented with a leukaemic NHL with lymphocytes of 10.2x109/l and 43.506 t(14;18)
positive cells per 75.000 cells in the peripheral blood. While clinically a complete remission was
seen after SCT, molecular analysis demonstrated still persistence of disease, that increased
before clinical evidence of relapse. After single treatment with DLI a complete clinical and
molecular remission was achieved, now lasting for 70+ months. Only limited chronic GVHD
was seen after DLI [13].
In the second patient (figure 2) samples for molecular monitoring of disease were available
since SCT. Almost complete clearing of t(14;18) positive cells from the blood was seen after
SCT while clinically a complete remission was observed. The number of t(14;18) positive cells
increased at clinical relapse, six years after SCT. Treatment with combination chemotherapy,
initiated to induce a rapid response of the relapse causing ischaemic colitis, failed. DLI resulted
Figure 2. clinical and molecular data (analysed in blood lymphocyte fraction) of a patient with follicular
NHL, before and after SCT and subsequent DLI
Abbreviations: see abbreviations at figure 1
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in a clinical and molecular complete remission lasting for 24+ months. Acute GVHD grade 2
and limited chronic GVHD occurred.
Figure 3 shows clinical and immunophenotypic data of a third patient, presenting with a
CD5+ CD19+ small lymphocytic NHL. Immunophenotypic results were available since
relapse after SCT. At that time in the peripheral blood the white blood cells were 8x109/l and
the lymphocytes 2.6x109/l. After DLI as single therapy percentages of CD5+ CD19+ cells of
B-lymphocytes were 53 and 60 in peripheral blood and bone marrow respectively, both
decreasing to percentages in the normal range while clinically a complete response was observed.
In one patient with relapsed follicular NHL after SCT t(14;18) positive cells could be
detected in the peripheral blood taken just before DLI (2.960 t(14;18) positive cells per 75.000
cells), but unfortunately, no follow up samples were present. In the two remaining patients with
follicular NHL pre-DLI blood samples were t(14;18) negative in one and were not available in
the other.
Figure 3. clinical, haematological and immunophenotypic data (analysed in the B-lymphocyte fraction of
bone marrow (BM) and peripheral blood (PB) samples) of a patient with small lymphocytic NHL, after DLI
Abbreviations: see also abbreviations at figure 1; leuko = absolute number of circulating leukocytes;
lympho = absolute number of circulating lymphocytes
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Discussion
Here we have shown the graft-versus-lymphoma effect of infusion of lymphocytes derived from
the original stem cell donor in seven consecutive patients with indolent lymphoma relapsed
after allogeneic stem cell transplantation. Incidence of graft-versus-host disease after DLI is low.
Clinical responses are illustrated with molecular data in two and with immunophenotypic data
in one patient, demonstrating in detail the efficacy of DLI.
Treatment of patients with indolent lymphomas remains a dilemma. Initially, a wait and see
policy is allowed in an asymptomatic patient. Once therapy is indicated temporal responses are
generally seen to several treatment modalities and regimens for years. To overcome the ever
relapsing nature of this lymphoma, ultimately being the cause of death, intensive myelo-
ablative treatment followed by allogeneic SCT has been initiated in selected patients, expecting
that a graft-versus-lymphoma effect will exist. Yet, relapses are still occurring after allogeneic
transplantation with reported relapse rates ranging from 0 to 29% three years after SCT for
chemotherapy sensitive or resistant disease [1-3]. As shown here, indolent lymphomas that
relapse after SCT are still responding to DLI.
The indolent lymphoma patients described here, were all poor-risk patients, being rela-
tively old at time of SCT for relapsed disease. All reached complete remission after SCT. As
expected, in case of relapse it occurred after a rather long period of time after SCT. Only two of
four evaluable patients responded to the chemo-, radio- or anti-CD20 therapy prior to DLI,
instituted for clinically threatening relapses. All patients responded to DLI, with predominantly
limited GVHD. The two deaths were caused by infectious disease in one patient and liver
failure of unknown cause in another patient.
Real-time PCR monitoring of t(14;18) positive cells, as shown in two follicular lymphoma
patients, correlated well with the clinically observed complete remission to DLI, with completely
clearing of lymphoma cells from the peripheral blood, as well as from the bone marrow in one
patient. During clinical remission after allogeneic SCT of both patient #1 and #2, lasting for
two and six years respectively, molecular analysis was still showing circulating lymphoma cells
in high and low numbers respectively, thus corresponding with residual disease. Both patients
showed correlating molecular and clinical results late in the course of follicular NHL. On the
other hand, earlier in the course of disease i.e. after first-line therapy, we could not find a
correlation between circulating t(14;18) positive cells and clinical disease status [19].
Immunophenotypic data in the third patient treated with DLI again correlated with clinical
findings, with disappearance of CD5+ CD19+ clone of the peripheral blood and bone marrow
in complete remission after DLI.
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We conclude that infusion with donor lymphocytes is an effective treatment for indolent
lymphoma relapsed after SCT, without severe GVHD. In this clinical setting, monitoring
numbers of t(14;18) positive cells in follicular lymphoma appeared to correlate with residual
disease activity and subsequent achievement of a ‘real’ complete remission after DLI.
Acknowledgements
We kindly thank Evelyn Tönnissen (Central Hematology Laboratory, University Medical Centre Nijmegen,
The Netherlands) for technical assistance.
References
1. Verdonck LF, Dekker AW, Lokhorst HM, et al. Allogeneic versus autologous bone marrow
transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma.
Blood 1997;90:4201-5.
2. Van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for
low grade lymphoma. Blood 1998;92:1832-6.
3. Mandigers CMPW, Raemaekers JMM, Schattenberg AVMB, et al. Allogeneic bone marrow
transplantation with T-cell depleted marrow grafts for patients with poor-risk relapsed low-
grade non-Hodgkin’s lymphoma. Br J Haematol 1998;100:198-206.
4. Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase
chain reaction in peripheral blood is significantly less predictive for relapse than detection in
bone marrow. Blood 1994;83:3800-7.
5. Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic
rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1997;15:445-50.
6. Jones RJ, Ambinder RF, Piantadosi S, et al. Evidence of a graft-versus-lymphoma effect
associated with allogeneic bone marrow transplantation. Blood 1991;77:649-53.
7. Van Besien KW, De Lima M, Giralt SA, et al. Management of lymphoma recurrence after
allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
Bone Marrow Transplant 1997;19:977-82.
8. Bär BMAM, Schattenberg A, Mensink EJBM, et al. Donor leukocyte infusions for chronic
myeloid leukemia relapsed after allogeneic bone marrow transplantation.
J Clin Oncol 1993;11:513-9.
9. Kolb HJ, Schattenberg A, Goldman JM, et al for the European Group for Blood and Marrow
Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor
lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
10. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with
relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44.
11. Verdonck LF, Lokhorst HM, Dekker AW, et al. Graft-versus-myeloma effect in two cases.
Lancet 1996;347:800-1.
12. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in
relapsed multiple myeloma after allogeneic bone marrow transplantation.
Blood 1997;90:4206-11.
13. Mandigers CMPW, Meijerink JPP, Raemaekers JMM, et al. Graft-versus-lymphoma effect of
donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18).
Lancet 1998;352:1522-3.
14. De Witte T, Hoogenhout J, de Pauw B, et al. Depletion of donor lymphocytes by counterflow
centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic
marrow transplantation. Blood 1986;67:1302-8.
Donor lymphocyte infusions
83
15. Verdonck LF, de Gast GC, van Heugten HG, et al. A fixed low number of T cells in HLA-
identical allogeneic bone marrow transplantation. Blood 1990;75:776-80.
16. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in
human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304
17. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man; a
long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
18. Meijerink J, Mandigers C, Van de Locht L, et al. A novel method to compensate for different
amplification efficiencies between patient DNA samples in quantitative real-time PCR.
J Mol Diagn, Part B of Am J Pathol 2001;3:55-61.
19. Mandigers CMPW, Meijerink JPP, Mensink EJBM, et al. Lack of correlation between numbers
of circulating t(14;18) positive cells and response to first-line treatment in follicular lymphoma.
Blood 2001;98:940-4.
84
Chapter 7
t(14;18) after first-line treatment
85
C.M.P.W. Mandigers, J.P.P. Meijerink, E.J.B.M. Mensink, E.L.R.T.M. Tönnissen,
K.M. Hebeda, M.J.J.T. Bogman, J.M.M. Raemaekers, on behalf of the Interzol
(South-East Netherlands Comprehensive Cancer Centers Cooperative Group)
C H A P T E R
8
Lack of correlation between numbers of
circulating t(14;18) positive cells
and response to first-line treatment
in follicular lymphoma
Blood 2001:98:940-944
86
Chapter 8
Abstract
Background: In follicular lymphoma the t(14;18) status of the peripheral blood and bone
marrow analysed by polymerase chain reaction (PCR), is assumed to correlate with disease
activity in patients with relapsed disease. Here we report on the clinical significance of
quantitating circulating lymphoma cells by real-time PCR in patients on first-line treatment.
Patients and methods: Thirty-four consecutive patients with previously untreated follicular
lymphoma and detectable t(14;18) positive cells in pre-treatment peripheral blood samples,
were monitored. All patients were treated with standard chemotherapy in combination with
interferon-alpha 2b. Before and after induction therapy blood samples were taken for quantita-
tive analysis of t(14;18).
Results: At presentation, a median of 262 t(14;18) positive cells per 75.000 normal cells was
found (range 1-75.000). Patients presenting with lower numbers of circulating tumour cells had
more frequently bulky disease (p=0,02). Seventy-nine percent of the patients responded
clinically to treatment. In 22/28 patients the number of circulating t(14;18) positive cells
decreased to undetectable or low levels after therapy, including four patients in whom treat-
ment had failed clinically. In the remaining responding patients circulating tumour cells per-
sisted after therapy.
Conclusion: These quantitative data on circulating t(14;18) positive cells question the
usefulness of molecular monitoring of the blood in a group of follicular lymphoma patients,
uniformly treated with a non-curative first-line regimen. t(14;18) Positive cells decreased in
peripheral blood after treatment, irrespective of the clinical response. Therefore, the significance
of so-called molecular remission should be reconsidered in follicular lymphoma.
t(14;18) after first-line treatment
87
Introduction
Follicular non-Hodgkin’s lymphoma (NHL) is characterised by the chromosomal translocation
t(14;18)(q32;q21) [1], leading to overexpression of bcl-2 with subsequent inhibition of
apoptosis [2]. Presence of t(14;18) positive cells, analysed by polymerase chain reaction (PCR),
is assumed to correlate with lymphoma activity. However, until now the clinical significance of
the presence or absence of t(14;18) positive cells in bone marrow and peripheral blood has not
been settled [3-7]. Quantitation of circulating t(14;18) positive cells, showing variation at
diagnosis and over time, may lead to a better understanding of the natural course of the
disease and the effects of treatment.
Previously we observed an excellent correlation between numbers of t(14;18) positive cells
in peripheral blood, analysed by real-time PCR, and the graft-versus-lymphoma effect of donor
leukocyte infusion in a patient with follicular NHL relapsing after allogeneic bone marrow
transplantation (BMT) [8]. Here, we present the results of prospective monitoring of circulating
t(14;18) positive cells by real-time quantitative PCR before and during first-line treatment of
patients with follicular lymphoma, consisting of standard chemotherapy in combination with
interferon-alpha 2b, followed by interferon-alpha 2b maintenance therapy [9,10].
Patients and methods
Patients
In December 1994 the South-East Netherlands Comprehensive Cancer Centers Cooperative
Group (Interzol) started an open non-randomised t(14;18) monitoring study in patients with
previously untreated follicular NHL of low-grade malignancy in Ann Arbor stages II bulky (> 5
cm), III and IV. The histological diagnoses of the original lymph node biopsies were reviewed
centrally according to the REAL-WHO classification. Furthermore, presence of t(14;18) in the
biopsies was analysed performing conventional PCR (KH and JvK). Informed consent was
obtained in all patients to collect blood samples for t(14;18) monitoring. Before start of
treatment circulating t(14;18) positive cells with a bcl-2 gene breakpoint in the major break-
point region (MBR) were identified in 34 consecutive patients. In these patients circulating
t(14;18) positive cells were quantitated prior to the start of treatment, after induction therapy,
and 3-monthly thereafter. Peripheral blood leukocyte and lymphocyte counts were recorded at
all time points of t(14;18) sampling. All patients were treated with eight 4-weekly CVP-courses
(cyclophosphamide 750 mg/m2 intravenously at day 1, vincristine 2 mg intravenously at day 1,
and prednisone 60 mg per day orally at days 1-5), in combination with interferon-alpha 2b
(5x106 IU subcutaneously 3 times a week). Thereafter, responding patients continued treatment
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with interferon-alpha 2b maintenance therapy (5x106 IU subcutaneously 3 times a week), until
intolerable toxicity, progressive disease or death. An initial wait and see period was allowed
before starting induction therapy.
Molecular analysis
Unmanipulated whole blood samples were directly frozen at -20°C and stored in the participat-
ing center until transport on dry ice to our laboratory for DNA isolation and subsequent
molecular analysis.
Cells carrying t(14;18) with a bcl-2 gene breakpoint in the major breakpoint region were
quantified performing real-time PCR analysis using Taq  polymerase and an internal probe in
the ABI/PrismTM 7700 sequence detector (Applied Biosystems, Fostercity, California, U.S.A.)
[11]. For this, 500 ng of DNA of each patient sample, measured by optical density at 260 nm,
was amplified in duplicate in the presence of 300 nM MBR-2 (5’-TCC CTT TGA CCT TGT
TTC TTG A-3’) and JH-con oligonucleotides [12], 200 nM of dual-labelled fluorogenic MBR
internal probe (5’-(FAM)-CAC AGA CCC ACC CAG AGC CC-(TAMRA)-3’), 250 µM dNTPs,
1.25 U of AmpliTaq goldTM DNA polymerase and 4 mM MgCl2 in sample buffer A (Applied
Biosystems) in a total volume of 50 µl. Samples were heated for 10’ at 95oC and amplified for
50 cycles of 15” at 95oC and 60” at 60oC. In parallel reactions, 500 ng of patient DNA was
amplified in duplicate in the presence of 300 nM of albumin forward (5’-TGA AAC ATA CGT
TCC CAA AGA GTT T-3’) and reverse primer (CTC TCC TTC TCA GAA AGT GTG CAT AT-
3’), 200 nM of dual-labelled fluorogenic albumin probe (5’-(JOE)-TGC TGA AAC ATT CAC
CTT CCA TGC AGA-(TAMRA)-3’, 250 µM dNTPs, 1.25 U of AmpliTaq goldTM DNA polymer-
ase and 4 mM MgCl2 in sample buffer A in a total volume of 50 µl. Amplification conditions for
the albumin reaction were as mentioned above. Since the t(14;18) and albumin reactions had
equivalent amplification efficiencies (E=0.91±0.05 and E=0.93±0.04 respectively) [13], the
t(14;18) PCR signal, reflecting the total number of lymphoma cells, was directly normalised to
the albumin PCR signal, reflecting the total number of cells used in the assay. For quantitation,
normalised patient PCR signals were compared to a single calibrator sample using the com-
parative Ct-method. Briefly, for each patient sample, the t(14;18) PCR Ct-value, i.e. the cycle
number at which emitted fluorescence exceeds the 10 times standard deviation of base-line
emissions as measured between cycle 3 to 15, is normalised to the albumin PCR Ct-value by
subtracting the albumin Ct-value from the t(14;18) Ct-value (∆CtS). All patient samples are
quantified against normalised Ct-values of a calibrator sample (∆CtC) using the following
equation:
⇒ XSample = XCal ∗2− ∆Cts −∆Ctc( ) = 750 ∗ 2− ∆∆Ct
t(14;18) after first-line treatment
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whereby XSample is the number of t(14;18) lymphoma cells per 500 ng patient sample DNA.
The calibrator sample was a 100-fold dilution of t(14;18) positive cell line SU-DHL-6 into a
DNA pool obtained from four EBV-induced lymphoblastoid B-cell lines, with 750 t(14;18)
carrying lymphoma cells per 500 ng of DNA (equivalent to 75.000 cells). The sensitivity limit of
our real-time PCR assay equals a single lymphoma cell in a background of 75.000 normal cells
(data not shown). Earlier we already showed that even after independent sampling, DNA
isolation and quantitation, the variation in results is within one log difference [8]. All patient
t(14;18) PCR products had been resolved on agarose gel to exclude PCR positivity due to
contamination, revealing a unique PCR product compatible with a unique chromosomal
rearrangement for each patient. In 25 of 30 analysed lymph nodes we were able to confirm
lymph node t(14;18) MBR positivity performing conventional PCR. Presence of t(14;18) has
been reported in benign lymphoid tissue [14] and in blood of healthy persons [15,16,17]. In
order to establish the lower noise level of our PCR, we analysed t(14;18) in blood of healthy
individuals. In 15 of 102 of them (15%) we found circulating t(14;18) positive cells. Eight
persons had 1 positive cell per 75.000 cells, and seven had 2-7 positive cells per 75.000 cells.
For nine PCR products we were able to determine the 14q+ breakpoint sequence that was
unique for each individual. These sequences did not differ from that of the chromosomal
breakpoint regions observed in follicular NHL patients, but none of the sequences was identical
to that obtained previously in our laboratory, thereby excluding contamination. Recently, in a
larger group of again healthy individuals presence of circulating t(14;18) positive cells in about
the same numbers, analysed with real-time PCR, was reported [17].
Statistical analysis
Patient characteristics between groups were compared with the chi-square test (level of signifi-
cance: p-value < 0.05). Progression-free survival was measured from the time of starting
induction therapy with CVP and interferon-alpha until the time of progression or until the end
of the observation period in non-progressive patients. Ending protocol treatment due to other
causes than progressive disease, e.g. intolerable toxicity or death from other diseases than
malignant lymphoma, was censored. If a patient had had an initial wait and see policy,
progression-free survival was still measured from the date of starting induction therapy. Survival
curves were calculated according to the Kaplan and Meier method; the log rank test was used
for analysing differences between curves.
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Results
Clinical characteristics
Table 1 summarises the clinical characteristics of the 34 patients having circulating t(14;18)
positive cells at presentation. Seventy-nine percent of the patients responded to induction
therapy with 8 CVP courses combined with interferon-alpha 2b. After a median follow-up of 44
months (range 8-69), the median progression-free survival of patients was 23 months. The
median overall survival has not been reached yet.
Quantitative t(14;18) at diagnosis
In blood samples taken before the start of treatment the median number of t(14;18) positive
cells was 262 (range 1 – 75.000) per 75.000 cells. Table 2 shows the clinical characteristics of
patients with high numbers (≥262 per 75.000 cells) and low numbers (up to 262 per 75.000
cells) of t(14;18) positive cells. In patients with the higher numbers of t(14;18) positive cells,
stage IV disease (mostly due to bone marrow involvement) was more frequent than in those
with the lower numbers (p=0,01). On the other hand, bulky disease was more often present in
patients with the lower numbers of circulating t(14;18) positive cells (p=0,02). The highest
numbers of t(14;18) positive cells at presentation were found in the two patients with overt
leukaemic NHL with lymphocyte counts of 15 and 22 x109/l respectively (patients nr. 1 and 2).
Progression-free survival curves of patients with the higher and the lower numbers of
circulating t(14;18) positive cells before therapy are shown in figure 1. Here, in the patients
with lower numbers we excluded those with up to 10 circulating t(14;18) positive cells per
75.000 cells, as this number approximates the maximum number of t(14;18) positive cells we
and others [17] found in the blood of healthy individuals performing real-time PCR analysis.
The progression-free survival did not differ between these groups (p=0,26). Even if the patients
with pre-treatment 1-10 circulating t(14;18) positive cells per 75.000 cells were included in the
group of patients with lower numbers, progression-free survival of this group did not differ from
the group presenting with higher numbers (p=0,23) (data not shown).
Sequential quantitative t(14;18) monitoring
In 28 patients t(14;18) positive cells could be quantitated in paired blood samples, taken before
and after induction treatment with CVP and interferon-alpha.2b (table 3). In all but one the
number of circulating t(14;18) positive cells dropped, irrespective of the clinical response. In 13
patients t(14;18) could not be detected anymore after treatment. Twelve of them had a clinical
response, but one showed progressive disease. In 9 patients numbers of t(14;18) dropped to
low levels of 1-10 per 75.000 cells, while treatment had failed in three of these. One of them
t(14;18) after first-line treatment
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Table 1. Clinical data of 34 patients with follicular lymphoma and pre-treatment circulating t(14;18)
positive cells.
n %
sex male 21 62
female 13 38
age median (years) 52
range (years) 30-79
Ann Arbor stage stage II bulky or III 11 32
stage IV 23 68
systemic symptoms   7 21
bulky disease 17 52
bone marrow involvement* 23 72
leukaemic   2   6
previous wait and see policy n   7 21
median period (months) 20
range (months) 9-32
response to 8 CVP + IFN complete remission 16 44
partial remission 11 34
stable disease   2   6
progressive disease   5 16
end of protocol treatment# insufficient response to induction   7 29
toxicity of induction   3 13
progression during maintenance   9 37
toxicity of maintenance   5 21
abbreviations: n = number; CVP = cyclophosphamide, vincristine and prednisone courses; IFN =
interferon alpha 2b
* bone marrow examination performed in 32 of 34 patients
# 24 of 34 patients ended treatment according to the protocol, others continued treatment
Table 2. Clinical characteristics related to the number of t(14;18) positive cells per 75.000 cells in blood
prior to start of therapy.
t(14;18) 1-262 t(14;18) ≥ 262 p
(n=17) (n=17)
stage IV 47% 88% 0.01
involved bone marrow* 50% 94% 0.01
bulky disease 71% 29% 0.02
prior wait and see 29% 12% n.s.
abbreviation: n = number; n.s. = not significant
*analysed in 32/34 patients
(patient nr. 5) was the only patient, who in retrospect did not present with a low-grade lym-
phoma but presented with a discordant NHL, with a small cell component in lymph node and
bone marrow, and a large cell component in the femur. After induction therapy progressive
disease of the large cell type was found in lymph node and femur, which was therapy-resistant.
Finally, in four responding patients, the numbers decreased, but remained positive at levels of
92
Chapter 8
12, 79, 177 and 361 per 75.000 cells respectively, whereas in one patient a decrease to 11 per
75.000 cells was found while treatment failed.  In most patients, circulating t(14;18) positive
cells decreased by one or more logs after induction therapy. Analysis of absolute leukocyte and
lymphocyte counts in the blood before and after induction showed that the decrease in
t(14;18) was not due to leukopenia or lymphopenia per se. As induction treatment led to a
decrease in the median number of t(14;18) positive cells from 262 to 1 per 75.000 cells, it led
to a decrease in the median numbers of leukocytes from 7.5 to 4.0x109/l and that of
lymphocytes from 1.3 to 0.7x109/l.
Only one patient (nr. 33) showed an increase after induction therapy from 1 to 406
circulating t(14;18) positive cells per 75.000 cells. This patient presented with a stage IVB bulky
follicular NHL with bone marrow localisation, and reached a partial remission after induction
therapy. In the original lymph node biopsy of this patient t(14;18) could not be demonstrated.
The course of t(14;18) in the peripheral blood in this patient remains unexplained.
low numers of
t(14;18)
high numbers of 
t(14;18)
0
0,2
0,4
0,6
0,8
1
0 12 24 36 48 60 72
months
Figure 1. progression-free survival (measured from start of induction therapy until progressive disease or
until end of observation period in non-progressive patients) of 34 patients with high (≥ 262) and low
numbers (10-262) of circulating t(14;18) positive cells prior to treatment (t= end of observation period of
individual patients) (p=0,26, log rank test).
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Table 3. Clinical data and circulating t(14;18) positive cells before and after induction treatment (patients
numbered according to numbers of t(14;18) positive cells before induction).
patient stage bone bulky response to t(14;18) t(14;18) t(14;18)
marrow disease induction lymph node before induction# after induction#
1 IV* + - PR + 76145 1
2^ IV* + - PR + 31890 3
3 IV + + PD + 8573 n.d.
4 IV + + PD + 2467 n.d.
5 IV + + PD + 2217 10
6 IV +  - PR + 1779 1
7 III  -  - CR + 1706 12
8 IV +  - CR n.d. 1684 n.d.
9^ IV + + PR + 1657 361
10 IV +  - CR + 1410 n.d.
11 IV +  - CR + 1234 0
12 IV + + PR + 991 79
13 IV +  - CR + 436 1
14 IV +  - CR + 351 1
15 IV +  - PR + 319 0
16 III n.d.  - CR n.d. 311 0
17 IV +  - PR + 277 177
18 IV +  - CR + 247 0
19 II  - + SD n.d. 80 11
20 IV + + CR n.d. 71 0
21 III n.d. + PR + 70 0
22 II  - + CR + 63 0
23 III  - + CR + 34 0
24^ III  - + CR + 25 5
25 II  - + PD - 24 1
26 IV +  - CR + 16 0
27 IV + + SD + 16 1
28^ III  -  - CR - 10 n.d.
29 IV +  - CR + 7 n.d.
30^ IV + + PR - 3 0
31^ III  - + PD + 2 0
32 III  - + CR - 1 0
33^ IV +  - PR + 1 0
34 IV + + PR - 1 406
abbreviations: # = number of circulating t(14;18) positive cells per 75.000 cells; ^ = previous wait and
see policy; * = leukemic; n.d. = not done; CR = complete remission; PR = partial remission; SD = stable
disease; PD = progressive disease; t(14;18) lymph node + = present (analysed by conventional PCR in
patients 1-31 and 33 and by karyotyping in patient 32); t(14;18) lymph node - = absent; t(14;18) lymph
node n.d. = not done; t(14;18) blood = number of circulating t(14;18) positive cells per 75.000 cells
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Discussion
This is the first report on prospective quantitative monitoring of t(14;18) positive cells in the
blood of patients with follicular lymphoma receiving first-line treatment. In this multicenter
study we used peripheral blood as source for t(14;18) analysis, as serial bone marrow analyses
are less attractive due to patient inconvenience and sampling error, and serial lymph node
sampling is not feasible either.
Thus far, only qualitative t(14;18) studies in follicular lymphoma have been reported in
literature, with conflicting results with regard to the clinical significance. Several authors claimed
that the risk of relapse after autologous stem cell transplantation and after standard chemo-
therapy correlated with the presence of t(14;18) in bone marrow or peripheral blood at the
time of treatment or shortly thereafter [5-7]. However, others found persistently t(14;18)
positive blood samples in patients with long lasting remissions [3,4]. These patients however
have been followed predominantly by clinical examination, making statements on real remis-
sion status impossible.
The median number of circulating t(14;18) positive cells in this study was 262 per 75.000
cells (= 3,5 in 1.000 cells) before start of therapy, with only six patients presenting with low
numbers of 1-10 per 75.000. Patients with stage IV disease and bone marrow involvement,
were more likely to have higher numbers of t(14;18) positive cells than those with less ad-
vanced stages. This finding can be considered to reflect the systemic dissemination of stage IV
disease. In contrast, patients presenting with bulky disease were more likely to have lower
numbers of circulating t(14;18) positive cells than those presenting without bulky disease. This
finding may be explained by an increased expression of adhesion receptors, such as L-selectin,
in bulky lymphoma, resulting not only in formation of a large contiguous tumour mass, but also
in preferential homing of lymphoma cells in lymph nodes rather than in bone marrow and
peripheral blood [18].
Our finding that the progression-free survival of patients with pre-treatment higher num-
bers of circulating t(14;18) positive cells did not differ from that of patients with lower numbers
suggests that the lymphoma load in the peripheral blood at presentation does not influence
prognosis. First-line treatment appears to result in an easy clearing of lymphoma cells from the
blood, irrespective of their numbers. In contrast, this therapy may not always affect other
compartments of disease, such as lymph nodes or bone marrow, from which progressive
disease may originate later on in the course of the disease.
Earlier we observed a clear correlation between numbers of t(14;18) positive cells in blood
and bone marrow, and the post-BMT course of a patient with a follicular NHL [8]. In this
patient t(14;18) positive cells persisted in the blood after allogeneic BMT and increased before
t(14;18) after first-line treatment
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clinical relapse. After subsequent donor leukocyte infusion t(14;18) positive cells in blood and
bone marrow decreased gradually while the patient responded clinically. A similar course was
seen in another follicular lymphoma patient treated with an allogeneic BMT, in whom clinical
findings correlated well with molecular analysis of t(14;18) positive cells, quantitated by a
competitive PCR-method [19]. These findings suggested a contribution of monitoring t(14;18)
positive cells in predicting response and relapse in follicular lymphoma patients, as also
assumed by Hirt et al, quantitating circulating t(14;18) positive cells in follicular lymphoma
patients treated with autologous bone marrow transplantation [20].
Real-time quantitative t(14;18) monitoring in serial blood samples in this previously
untreated patient group, showed a sharp decrease in t(14;18) positive cells after a rather
conventional therapy with CVP and interferon-alpha, regardless of the clinical response. This
decrease in t(14;18) cannot be explained by a parallel lowering of circulating white blood cells.
In most responders to induction therapy we found a considerable decrease or even disappear-
ance of circulating t(14;18) positive cells. When a molecular remission in follicular lymphoma
patients would be indicative of cure or at least prolonged remissions, disappearance of t(14;18)
positive cells cannot be expected after a non-curative treatment with CVP and interferon-alpha.
Remarkably, even in the five non-responders we observed a similar decrease in t(14;18).
Increasing the sensitivity of this real-time PCR analysis of t(14;18) will not contribute to
understanding the course of t(14;18), as this PCR is already capable of detecting t(14;18)
positive cells in healthy individuals. A longer follow-up period with more consecutive samples
for t(14;18) analysis will give information on variation in circulating t(14;18) positive cells
during and off maintenance therapy.
It cannot be excluded that interferon-alpha plays a role in the decrease of t(14;18) positive
cells after induction therapy. Therefore we quantitated circulating t(14;18) positive cells in
another group of previously untreated follicular lymphoma patients (stage III and IV), who were
treated with 8 CVP-courses without interferon-alpha 2b according to a European protocol
(EORTC 20963 / HOVON 35). In this study 19 patients had pre-treatment circulating t(14;18)
positive cells with a bcl-2 gene breakpoint in MBR, with a median number of 23 per 75.000
cells (range 1 – 5.027). After induction therapy again irrespective of clinical response, a sharp
decrease in circulating t(14;18) positive cells to (nearly) undetectable levels was observed in all
12 patients whose blood  was serially tested (data not shown). From these data we conclude
that it is unlikely that treatment with interferon-alpha per se causes the decrease in circulating
t(14;18) positive cells in the patient group presented here.
The observation in this study that in most patients circulating t(14;18) positive cells
decreased or disappeared after induction therapy, regardless of clinical response, should urge
for a reappraisal of so-called molecular remissions. At least after this conventional first-line
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treatment, monitoring t(14;18) positive cells in the peripheral blood does not correlate with
lymphoma activity. Whether correlations are more reliable in pre-treated patients with more
advanced disease, as suggested in studies of high-dose therapy and stem cell transplantation
[5,7,8,19], has to be analysed in future prospective monitoring studies.
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Abstract
In the present study, disease parameters and response to treatment were compared with
quantitative data of circulating t(14;18) positive cells for 56 follicular NHL patients receiving
first-line or subsequent-lines of conventional treatment. A total number of 75 treatment
episodes were investigated. Numbers of circulating t(14;18) positive cells were determined by
real-time PCR technique. A content of more than 328 cells per 75.000 cells in peripheral blood
samples prior to therapy correlated with stage IV disease (P=.01), bone marrow involvement
(P≤.01) and overt leukaemic lymphoma (P=.04). Therapy-episodes that cleared circulation
from t(14;18) positive cells with more than one log resulted in a significantly longer progres-
sion-free survival than treatment episodes with less than one log decline (26 versus 12 months
respectively) (P<.01). After first-line treatment episodes, numbers of circulating t(14;18)
positive cells mainly declined irrespective of clinical response. For episodes with 2nd or later
lines of treatment, declining numbers of lymphoma cells correlated with a clinical remission,
whereas increasing numbers of lymphoma cells were associated with clinically stable or
progressive disease. From this, we conclude that quantitation of circulating t(14;18) positive
cells in peripheral blood is of little clinical significance for the individual follicular lymphoma
patient.
t(14;18) after first and subsequent lines of treatment
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Introduction
Advanced-stage follicular non-Hodgkin’s lymphoma (NHL) is characterised by an indolent
course of disease and repeated relapses on conventional treatment. New approaches are being
evaluated such as high-dose treatment and monoclonal antibody therapy. The long-term
benefit of these new treatment modalities, if any, is still uncertain. Reliable methods to rapidly
evaluate the long-term efficacy of new treatments would be most welcome. Monitoring ‘mini-
mal’ residual disease by polymerase chain reaction (PCR) techniques has become popular in
this respect since up to one malignant cell in 105-106 normal cells can be detected. As most
follicular NHL contain the characteristic chromosomal translocation t(14;18), the resulting bcl-
2/IgH rearrangement can be used as a target for PCR analysis [1]. The presence or absence of
these t(14;18)-bearing cells could be useful as a marker for disease activity. In addition, the
real-time PCR technique, as described in 1996, allows for accurate quantitation [2]. The
concept of molecular remission has been introduced in evaluating response to treatment in
leukaemia’s, but also in follicular lymphomas. For repeated PCR analyses during the course of
disease, peripheral blood has been used as sampling source in many studies, with a neglectable
burden for patients. Thusfar, reports on the clinical significance of circulating t(14;18) positive
cells are not conclusive. Patients in long-term remission after first-line treatment may still have
detectable t(14;18) positive cells in the circulation without any clinical evidence of active
disease [3,4]. Lopez-Guillermo et al studied molecular response after a range of various first-
line treatments and concluded that patients who achieved a t(14,18)-negative status during the
first year of treatment had a significantly longer progression-free survival than those with
persistent circulating t(14;18) positive cells [5]. Others have found that the persistence of
t(14;18) positive cells after autologous stem cell transplantation (ASCT) was predictive of
subsequent relapse while recurrent disease developed less frequently in patients with no
detectable t(14;18) positive cells after ASCT [6-8]. However, in the latter two studies bone
marrow samples were used for PCR analysis instead of peripheral blood.
The data on quantitative monitoring are scarce. Previously we reported on the gradual
clearing of t(14;18)-bearing cells from the blood after allogeneic SCT, analysed with a competi-
tive t(14;18) PCR [9]. Hirt and Dölken demonstrated increasing numbers of t(14;18) positive
cells in peripheral blood prior to clinical relapse after ASCT whereas in patients with continuing
complete remission numbers remained low or negative [10]. We observed an excellent relation
between numbers of circulating t(14;18) positive cells, quantified by real-time quantitative PCR,
and the graft-versus-lymphoma effect of donor leukocyte infusion in a patient with follicular
lymphoma relapsed after allogeneic SCT [11]. These data suggested that quantitation of
t(14;18) positive cells in peripheral blood by real-time PCR could be an excellent and easily
accessible tumour marker.
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In a group of previously untreated patients who all received a combination of chemo-
therapy plus interferon-alpha as first-line treatment, we did not observe a relation between
clinical response and quantitative t(14;18) data in peripheral blood [12]. Since the presumed
clinical significance of so-called molecular remissions was mainly based on studies that include
second- and later-line treatments and since our findings during first-line treatment did not
confirm these conclusions, peripheral blood is perhaps not the most representative compart-
ment for measuring disease activity especially during early phases of disease. During progres-
sion of disease, after patients have received multiple treatment regimens, a leukaemic compo-
nent may become more prominent and consequently peripheral blood becomes representative
for the total number of malignant cells. Here, we present data on quantitative monitoring of
t(14;18) positive cells in peripheral blood using real-time PCR, after first-line and subsequent-
lines of treatment in patients with follicular lymphoma.
Patients and methods
Patients
We studied 75 conventional treatment episodes of patients with follicular NHL, all t(14;18)
positive. A treatment episode was defined as the period in which at regular intervals courses of
the same drug combination were given. For each treatment episode paired blood samples were
obtained, i.e. one sample taken within one month prior to start of therapy and the second
sample obtained within one month after the end of the episode. This way, more than one
treatment episode in a single patient can be studied as long as paired blood samples are
available. We excluded treatment episodes consisting of myelo-ablative therapy followed by
allogeneic stem cell transplantation, since these results will be addressed elsewhere (manuscript
in preparation). Clinical data at time of blood sampling for t(14;18) analysis were collected
from the medical records. Disease status was evaluated by standard staging procedures,
including physical examination, laboratory investigation, computed tomography of chest and
abdomen, and bone marrow trephine biopsies. A contiguous tumour mass of at least 5 cm.
was considered bulky. Leukaemic NHL was defined as a lymphoma with a number of circulat-
ing lymphocytes exceeding 5x109/l. Evaluation of clinical response to treatment was done using
standard criteria [13].
t(14;18) after first and subsequent lines of treatment
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Real-time PCR
Cells carrying t(14;18) with a Bcl-2 gene breakpoint involving the major breakpoint region
were quantified by real-time PCR analysis in the ABI/PrismTM 7700 sequence detector (Applied
Biosystems, Fostercity, CA, USA) [12]. Using 0.5 ug of genomic DNA template, the sensitivity
limit of this PCR is a single lymphoma cell in about 75.000 normal cells. We included treatment
episodes with numbers of circulating t(14;18) positive cells below a limit of 10 lymphoma cells
per 75.000 cells, as long as the original lymph node was known to be t(14;18) positive, despite
the fact that comparable small numbers of t(14;18) positive cells can be found in healthy
individuals [14].
Statistical analysis
Differences in clinical characteristics and responses to treatment between groups of patients
were compared with the chi-square test. Progression-free survival after a treatment episode was
measured from start of therapy until progressive disease. For this study the observation period
ended August 1rst, 2001. Survival curves were calculated according to the Kaplan and Meier
method; the log rank test was used for analysing differences between curves. A P-value of <.05
was considered statistically significant.
Results
Clinical characteristics
A total of 75 treatment episodes of 56 patients have been studied. The clinical characteristics
prior to treatment episodes are summarised in table 1. Stage IV disease was present in 66% of
the cases. An overt leukaemic blood picture was seen in four treatment episodes (5%) obtained
from three patients. Treatment consisting of CVP (cyclophosphamide, vincristine and pred-
nisone) or CVP-like schedules with or without interferon alpha-2b, was most frequent. First-line
treatment was given in 49 episodes (65%) and subsequent lines of therapy were administered
in the remaining 26 episodes. The majority of treatment episodes resulted in a clinical re-
sponse: complete response in 37% of episodes and more than fifty percent reduction of tumour
masses (PR) in 37% of episodes. In 25% of the episodes no clinical response (stable disease or
progression) was observed.
Pre-treatment numbers of circulating (14;18) positive cells
For five pre-treatment episodes, blood samples were not available for t(14;18) analysis. Not
surprisingly, the four cases with overt leukaemic lymphoma had the highest numbers of
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circulating t(14;18) positive cells before treatment (75.000, 43.506, 38.348 and 31.890 per
75.000 cells respectively). In 15/70 (21%) pre-treatment samples low numbers of circulating
t(14;18) positive cells of 0-10 per 75.000 cells were found, all these cases were found to be
t(14;18) positive in the diagnostic lymph node or bone marrow sample. For 55 pre-treatment
samples numbers of circulating t(14;18) positive cells exceeded 10 cells per 75.000 cells with a
median of 328 cells (range 10-75.000). Since the nature of t(14;18) positive cells for those
samples that have fewer than 10 positive cells per 75.000 cells is not clear, the pre-treatment
samples were defined into the following three subgroups, i.e. the first subgroup having less than
10 t(14;18) positive cells per 75.000 cells, the second subgroup having t(14;18) positive cells
between 10 and 328 (median) per 75.000 cells and the third subgroup having more than 328
t(14;18) positive cells per 75.000 cells (table 2). Clinical characteristics of the first subgroup did
not significantly differ from the second subgroup. For the third subgroup, stage IV disease and
bone marrow involvement was significantly more frequent compared to the second subgroup
(P=.01 and P<.01 respectively). There was no difference in clinical response rate between the
second and third subgroup.
Post-treatment numbers of circulating t(14;18) positive cells and clinical response
The clinical response to treatment related to the post-treatment numbers of circulating t(14;18)
positive cells is shown in table 3. All treatment episodes that did not result in a clinical complete
Table 1. Clinical data of 75 treatment episodes from 56 patients with follicular lymphoma.
n
treatment episodes 75
pre-treatment samples 70/75
post-treatment samples 64/75
Ann Arbor stage I / II   8
III 17
IV 49
bone marrow involvement* 48
bulky disease 27
leukaemic   4
treatment single agent 14
CVP (-like) alone 17
CVP + IFN 35
other   9
response to treatment complete remission 28
partial remission 28
stable disease   6
progressive disease 13
abbreviations: CVP = cyclophosphamide, vincristine, and prednisone courses; IFN = interferon-alpha-2b
*bone marrow examination performed prior to 68/75 episodes of treatment
t(14;18) after first and subsequent lines of treatment
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remission (CR), were combined into one subgroup i.e., partial remission (PR), stable disease
(SD) and progressive disease (PD). In 21 out of 24 samples for treatment episodes resulting in
a clinical CR, a decrease of circulating t(14;18) positive cells below the threshold of 10 cells per
75.000 cells was observed whereas only 24 out of 40 samples for treatment episodes resulting
in PR, SD and PD (P=.02) were below this threshold.
Decline in numbers of circulating t(14;18) positive cells and progression-free survival
The median PFS was 22 months (range 1-134) for 71 evaluable treatment episodes. Instead of
relating only relative numbers of circulating t(14;18) positive cells before and after treatment to
clinical response, we wondered whether the magnitude of decline over treatment would be
more predictive for the longevity of the clinical response as measured by the PFS (figure 1). For
this we divided the treatment episodes into two subgroups, for which the first subgroup had a
decline of more than one log of magnitude between the pre- and post treatment sample
Table 2. Clinical characteristics related to the numbers of circulating t(14;18) positive cells per 75.000 cells
before the start of therapy.
1-10 cells below  the median above  the median P*
(n=15) (%) of 328 (n=27) (%) of 328 (n=28) (%)
stage IV 53 54 86 .01
involved bone marrow 54 56 96 <.01
bulky disease 33 44 29 NS
overt leukaemic   0   0 14 .04
elevated LDH 27   9 29 NS
responder to therapy 87 70 71 NS
abbreviations: LDH = serum lactate dehydrogenase level; responder = complete or partial remission; NS
= not significant
*chi-square test between the group with t(14;18) below the median and t(14;18) above the median
Table 3. Response to treatment related to the numbers of circulating t(14;18) positive cells per 75.000
cells after treatment.
t(14;18) after treatment t(14;18) after treatment total P
  0-10 above 10
CR 21   3 24 .02
PR, SD, PD 24 16 40
total 45 19 64
abbreviations: CR = complete remission; PR = partial remission; SD = stable disease; PD = progressive
disease
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(n=32) whereas the second subgroup remained within one log (n=14). Episodes for which the
pre-treatment sample contained less than 10 circulating t(14;18) positive cells per 75000 cells
were discarded from this analysis, since the accuracy of the quantitative method is low for
those samples that have an estimated content of lymphoma cells below 1 t(14;18) positive cell
per 75.000 cells. The median PFS following a treatment episode in which a decline in t(14;18)
numbers exceeded one log was significantly longer than the PFS for the other subgroup: 26
versus 12 months (P<.01). This holds if only first line treatment episodes are considered: in the
35 evaluable episodes, the group with a decline of more than one log (n=24) had a signifi-
cantly longer PFS of 42 months than the group with less than one log decline (n=11) being 15
months (P =.04). The numbers of episodes after second- and later line treatment were too
small to permit further analysis (n=8 versus n=3 respectively).
Figure 1. Progression-free survival after 46 episodes of treatment for follicular lymphoma.
Progression-free survival was measured from the start of treatment episode until disease progression, or, in
episodes without disease progression, until the end of the observation period. In 32 episodes of treatment a
more than one log decrease in numbers of circulating t(14;18) positive cells before and after treatment
occurred and in 14 episodes less than one log decrease was observed (P<.01). (Merely, the episodes with
pre-treatment numbers of circulating t(14;18) positive cells exceeding 10 per 75.000 cells have been
included in this analysis). (♦ = end of observation period of individual patients)
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Changes in circulating t(14;18) positive cells comparing first- and subsequent lines
of treatment
We further investigated whether the magnitude of change in circulating t(14;18) positive cells
would be different for first- or subsequent lines of treatment episodes (n= 49 and n=26
respectively). The median number of circulating t(14;18) positive cells prior to first-line epi-
sodes was 276 (range 10-75.000) per 75.000 cells and prior to subsequent lines of treatment
622 (range 29-38.348) per 75.000 cells. For both groups, episodes were divided dependent on
clinical response to treatment i.e. reaching CR, PR or SD/PD. For 2nd or later lines of treatment
episodes, clinical CR was reached in only three episodes, all of which contained pre-treatment
samples with less than 10 circulating t(14;18) positive cells per 75.000 cells. For first-line
treatment episodes, circulating t(14;18) numbers declined irrespective of clinical CR or PR as
previously reported (12).
For first-line treatment, seven episodes resulted in clinical SD/PD with one episode having
a pre-treatment sample with less than 10 circulating t(14;18) positive cells per 75.000 cells
(table 4). During these episodes, the number of circulating t(14;18) positive cells declined even
for those episodes in which clinically progressive disease was documented. For subsequent
lines of treatment, only seven episodes were evaluable for which clinical SD (n=1) or PD
(n=6) was reached. During three episodes including the episode in which SD was reached,
numbers of circulating t(14;18) cells declined. Remarkably, in the four remaining episodes with
clinical progressive disease, t(14;18) numbers increased.
Table 4. Absolute numbers of circulating t(14;18) positive cells per 75.000 cells before and after first-line
and subsequent lines of therapy in non-responding patients.
SD*/PD§   before therapy after therapy
1rst line treatment
1* 80 11
2* 16 1
3* 215 1
4* 23 1
5§ 2217 10
6§ 24 1
7§ 2 0.1
≥ 2nd line treatment
1* 1368 315
2§ 29 6
3§ 38348 6345
4§ 1270 26814
5§ 327 3544
6§ 63 20207
7§ 90 52526
abbreviations: SD, stable disease, is given the * suffix; PD, progressive disease, is given the § suffix
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Discussion
For the individual patient with follicular NHL, quantitation of circulating t(14;18) positive cells
cannot be used to predict clinical characteristics nor response to treatment in general. Further-
more, peripheral blood appears not to be the most representative body compartment for
measuring clinical lymphoma activity. Surprisingly, the rate of clearing the blood compartment
from lymphoma cells is positively correlated with a prolonged progression-free survival. For
patients that demonstrate a rate of clearing of more than one log between the pre- and post-
treatment samples (obtained within one month prior to and after therapy respectively) the time
to progression was about twice as long compared to other patients.
Until now, the utility of qualitative or quantitative monitoring of residual lymphoma activity
remains controversial. We found excellent correlation’s in several individual cases in the past
[9,11]. However, much to our surprise we did not find a correlation in a group of patients
uniformly receiving first-line treatment [12]. Detailed analysis of the present data in a larger
group of patients suggests that results may depend on the phase of the disease at which blood
samples for t(14;18) analysis are obtained. Analysis of the extended group of patients receiving
first-line therapy compared to our previous study [12], again did not reveal a correlation
between clinical response to treatment and changes in numbers of circulating t(14;18) positive
cells. The number of circulating lymphoma cells declined after treatment, even for those
patients who developed clinical stable or progressive disease. In contrast, for the group of
patients with a long history of follicular lymphoma that received secondary or later lines of
treatment, decreasing numbers of circulating t(14;18) positive cells were almost exclusively
observed for treatment episodes that resulted in clinical remission.
At first glance, reports in literature seem to indicate that intensive therapies such as
allogeneic SCT with or without donor leukocyte infusion are really efficacious treatment
modalities for which molecular remissions can be reached [9,11]. However, these regimens are
mainly used as a secondary or later line of treatment and therefore primarily for patients with
advanced phase of disease. Residual disease content for these patients may truly be correlated
with response to therapy. The success of reaching a molecular remission in peripheral blood by
monoclonal antibody therapy like anti-CD20 as first-line treatment [15-17], may not reflect the
efficacy of treatment but rather the easy clearing of circulating lymphoma cells in patients with
less advanced phase of disease. In line with this explanation are our findings with front-line
CVP and interferon-alpha [12] as well as the present series showing that a relatively mild first-
line treatment can easily clear the blood from lymphoma cells, even without a clinical tumour
response.
t(14;18) after first and subsequent lines of treatment
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So, early in the course of disease peripheral blood is more easily cleared from lymphoma
cells than later on in the course of disease, suggesting that most follicular lymphomas more or
less behave like a classical tissue (i.e. nodal)-type of disease in the beginning. That means that
clearing the blood from lymphoma cells is not synonymous with overall tumour response in the
rest of the body, especially after first-line treatment. Later on in the course of disease, the
disappearance or strong clearing of t(14;18) positive cells from the blood correlates with the
clinical response to treatment for most patients, thus reflecting the leukaemic characteristics of
the lymphoma. It is attractive to speculate that ‘leukaemic’ propensity is accompanied with
further genetic aberrations in the course of disease [18,19]. In this regard, adhesion factors
affecting homing capabilities of the malignant cells may well be involved [20]. Further elucidat-
ing these mechanisms will help us understand how to optimally use quantitative monitoring of
numbers of circulating t(14;18) positive cells. For the moment we should take care to give too
much attention to the significance of so-called molecular remission when evaluating the merits
of systemic treatment regimens in patients with follicular lymphoma.
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Summary and discussion
Follicular lymphomas form a distinctive group of malignant lymphomas with a characteristic
course of ever relapsing disease, that ultimately - after histologic transformation - causes the
patients’ death years after diagnosis. Treatment of such patients remains a dilemma. Initially, a
wait and see policy is allowed in an asymptomatic patient. Once therapy is indicated, temporal
responses are seen to diverse treatment modalities and regimens. Unfortunately, in general,
only prolongation of progression-free but not overall survival is achieved by several therapies.
An exception to this rule seems to be the intensification of treatment to myelo-ablative therapy
followed by allogeneic stem cell transplantation. This way, patients can benefit not only by the
high-dose chemo- and radiotherapy, but also by an anti-tumour effect from the immuno-
reactive donor lymphocytes in the graft, the so-called ‘graft-versus-lymphoma’ effect. In
contrast to the lack of improvement of clinical outcome of patients with follicular lymphoma,
diagnostics have in fact greatly gained sensitivity during the past decades. With the introduction
of real-time polymerase chain reaction in molecular diagnostics, cells carrying the chromosomal
translocation t(14;18), characteristic for follicular lymphoma, can be quantified very sensitively.
It might be that molecular diagnostics will eventually help in tailoring treatment in individual
patients. Studies on these subjects are presented in this thesis.
Chapter 1 reviews insights in classification of the malignant lymhomas, and then focuses on
follicular lymphoma. Pathology, immunophenotype, and cytogenetics of follicular lymphoma
are discussed, followed by the clinical characteristics of patients. Furthermore, an overview of
treatment strategies is given, including the more recent therapies.
In chapter 2 the clinical results are presented of allogeneic bone marrow transplantation
(BMT) in patients with poor-risk relapsed indolent non-Hodgkin's lymphoma (NHL) in the
University Medical Centre Nijmegen. Conditioning regimen consisted of cyclophosphamide
and total body irradiation with or without additional idarubicin. Donors were HLA-matched
siblings. Their marrow was depleted of T-lymphocytes using counterflow centrifugation. Post-
BMT prophylaxis of graft-versus-host disease (GVHD) consisted of cyclosporin A. Fifteen
patients with a median age of 47 years were transplanted. All patients engrafted. After a
median follow up of 36 months (range 9-78), 10 patients were alive and in complete remission.
Two of them had relapsed after BMT but re-entered complete remission following infusions of
lymphocytes from the original bone marrow donor. Five patients died; causes of death were
cardiomyopathy (n=1), chronic GVHD (n=1) and infection during chronic GVHD (n=3).
Writing the summary of this thesis, I can give an update of these results. Until April 1rst,
2002 33 patients with low-grade NHL have been treated with an allogeneic stem cell transplan-
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tation. After a median follow up of 32 months (range 1-138) the progression-free and overall
survival rates are 79% and 55% respectively at 5 years. Acute GVHD ≥ grade 3 was seen in 3
of 32 patients (9%) and extensive chronic GVHD in 11 of 26 (42%). Three relapses of indolent
NHL occurred, all responding to therapeutic donor lymphocyte infusion (DLI). Prophylactic
DLI was given in three patients. One patient, treated with stem cells derived of a matched
unrelated donor after anti-thymocyte globulin containing conditioning, developed a post-
transplantation lymphoproliferative disorder.
Allogeneic T-cell depleted stem cell transplantation, although associated with complica-
tions, is an efficacious treatment for patients with poor-risk relapsed low-grade NHL.
As follicular lymphoma have an indolent course of disease with a median overall survival of
patients of 7-10 years, it will at least take years, if not decades, before a survival advantage in
fact can be attributed to a new therapy. Monitoring disease activity by molecular diagnostics
might play a role in evaluation of treatment efficacy earlier than by clinical means as e.g.
determining survival after therapy. Circulating lymphoma cells can now be determined by
qualitative, and more recently, quantitative polymerase chain reaction (PCR) analyses, using
the chromosomal translocation t(14;18) which is characteristic for follicular lymphoma.
We developed a real-time quantitative PCR of t(14;18), as described in chapter 3. As
compared to conventional PCR analyses, real-time PCR has low false-positivity by the use of a
closed system for amplification and detection. Positivity is determined in the exponential phase
of the reaction at the threshold cycle, which is proportional to the initial amount of t(14;18)
positive cells. The t(14;18) PCR signal, as a measure for lymphoma cells, is normalised to that
of β-actin, as a measure of the total amount of DNA. For quantitation, the normalised t(14;18)
signal is related to a calibrator sample.
Chapter 4 presents a novel method to handle a common problem in real-time quantitative
PCR, i.e. the differences in amplification efficiencies between DNA samples. In general, in
follicular lymphoma the amplification efficiencies of the t(14;18) and albumen PCR are higher
in blood samples than in lymph node samples, whereas within one sample both reactions have
equal efficiencies. In patient samples with a lower amplification efficiency as compared to the
calibrator sample, disease activity can be underestimated, especially in presence of very small
numbers of t(14;18) positive cells. To compensate for differences between amplification
efficiency of patient samples and the calibrator, two reference reactions are used, specific for β-
actin and for albumen housekeeping genes. Furthermore, in this way patient samples can be
recognised that are highly contaminated with PCR-inhibiting factors, affecting different amplifi-
cation reactions to a different extent, making accurate quantitation of disease activity impossible.
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With the introduction of the real-time PCR in molecular diagnostics, cells carrying the chromo-
somal translocation t(14;18) in follicular lymphoma can now be quantified with a sensitivity of
detecting 1 malignant cell out of 150.000 normal cells. At first thinking, one would expect the
number of circulating lymphoma cells to correlate with disease activity. Thus, a decrease in
circulating t(14;18) positive cells should be found in patients responding to therapy, and an
increase in subsequent relapse.
Indeed, as presented in chapter 5, in a patient with relapsed follicular NHL after alloge-
neic BMT, the graft-versus-lymphoma effect of a donor lymphocyte infusion could be substanti-
ated by real-time quantitative PCR analysis of t(14;18). A 48-year old female with relapsed
indolent follicular NHL was treated with myelo-ablative therapy, followed by infusion of a T-cell
depleted bone marrow graft of her HLA-identical sister. She did not develop graft-versus-host
disease. Twenty-two months later, a relapse of persistent low-grade malignancy was diagnosed
in initially involved lymph nodes and bone marrow. Single treatment with infusion of
lymphocytes of the original marrow donor gradually resulted in a complete remission, including
a lymphoma-negative bone marrow. Temporary complaints of a dry mouth, presumed to
represent limited chronic GVHD, were left untreated.
Over time lymphoma cells in peripheral blood and bone marrow of this patient were
monitored by real-time quantitative PCR analysis of t(14;18) positive cells. After BMT lym-
phoma cells persisted in blood and bone marrow while she was in clinical complete remission.
The number of lymphoma cells markedly increased before clinical relapse and subsequently
decreased to undetectable levels after DLI. This patient shows that real-time quantitative PCR
analysis of t(14;18) is a promising new technique to establish molecular disease status in
follicular NHL, that may prove useful in evaluating treatment efficacy and prognosis.
Chapter 6 reviews results of intensified treatment of patients with relapsed indolent non-
Hodgkin’s lymphomas with myelo-ablative therapy followed by autologous or allogeneic stem
cell transplantation (SCT). As several conventional therapies have resulted in an improved
disease-free survival but not in a prolonged overall survival, dose intensification by SCT is
being applied more and more. In both forms of SCT the anti-tumour effect of the high-dose
conditioning is used; furthermore the allogeneic transplantation has an additional graft-versus-
lymphoma effect. Therefore, allogeneic SCT appears to be promising and potentially curative
for a selected group of patients with an indolent lymphoma, despite complications as graft-
versus-host disease and treatment-related mortality. Early in the course of an indolent NHL,
especially at first relapse, an allogeneic SCT should at least be considered for a patient having
an HLA-compatible stem cell donor.
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In case of relapsed haematological disease after allogeneic SCT a remission can still be induced
by shifting the balance between patient and donor immuno-reactive cells in favour of the
donor, either by diminishing the patient’s immunosuppressive medication, or by infusion of
lymphocytes derived from the original stem cell donor.
Chapter 7 presents the graft-versus-lymphoma effect of donor lymphocyte infusions in
seven patients with relapsed indolent lymphomas after allogeneic SCT. In available bone
marrow and blood samples lymphoma cells were monitored by real-time quantitative PCR of
t(14;18) positive cells in follicular NHL, and by immunophenotyping in small lymphocytic
NHL. Before DLI, clinically threatening relapses necessitated treatment with chemo- and/or
radiotherapy in three patients, and with rituximab in one patient. Evaluable responses to pre-
DLI therapy were stable disease (n=1) and partial remissions (n=2). The relapsed lymphomas
gradually responded to DLI to complete remissions (n=4) and to partial remissions (n=3). In
three cases consecutive blood and/or bone marrow samples had been taken before and after
DLI. In all three, clinical responses could be substantiated by molecular or immunophenotypic
analysis of lymphoma cells. Five patients are alive and well; their responses to DLI are lasting
for a median of 30 (range 5-70) months. Two patients died 2 and 17 months after DLI of
Aspergillus fumigatus pneumonia and liver failure of unknown cause, respectively. After DLI
acute GVHD occurred in three patients, classified as grade 2, whereas only limited chronic
GVHD was seen (n=5). DLI is effective for treatment of indolent lymphoma relapsing after
SCT.
With excellent correlations between clinical and molecular findings found in the donor
lymphocyte infusion setting, we expected the number of circulating t(14;18) positive cells again
to correspond with clinical follicular lymphoma activity in other treatments. If so, molecular
diagnostics might be used in tailoring treatment in individual follicular NHL patients. Thus, e.g.
patients with molecular persistence of disease in clinical remission after therapy might be
considered for potentially curative treatment like allogeneic SCT earlier than at subsequent
clinical relapse.
In chapter 8 the clinical significance of quantitating circulating t(14;18) positive cells by
real-time PCR is reported in first-line treatment of follicular lymphoma. In a prospective study,
t(14;18) was monitored in the peripheral blood of 34 follicular lymphoma patients, uniformly
receiving standard chemotherapy in combination with interferon-alpha 2b. At presentation, a
median of 262 t(14;18) positive cells per 75.000 normal cells was found (range 1-75.000). This
number clearly exceeds the number of 1-10 t(14;18) positive cells per 75.000 cells we demon-
strated in the blood of 15 of 102 tested healthy individuals performing the real-time PCR. In
patients with numbers of circulating t(14;18) above the median, stage IV disease was signifi-
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cantly more frequent than in those with lower numbers. On the other hand, bulky disease was
significantly more frequent in the group with numbers of circulating t(14;18) below the median
than in that with higher numbers. In 22/28 patients the number of circulating t(14;18) positive
cells decreased to undetectable or low levels after therapy, including four patients in whom
treatment had failed clinically. In the remaining responding patients circulating lymphoma cells
persisted after therapy.
The quantitative data on circulating t(14;18) positive cells, as presented in chapter 8, question
the clinical significance of molecular monitoring of the blood in first-line non-curative treatment
of follicular lymphoma. On the other hand, late in the course of disease, i.e. in the donor
lymphocyte infusion setting, excellent correlations between clinical and molecular findings are
found. This suggests differences in (re-) appearance of t(14;18) positive cells in the peripheral
blood in follicular NHL over time.
Chapter 9 reports on the dynamics of circulating t(14;18) positive cells during first-line
and subsequent lines of treatment in follicular lymphoma. Disease parameters and response to
treatment were compared with real-time quantitative PCR data on circulating t(14;18) positive
cells for 56 follicular NHL patients receiving first or subsequent-lines of conventional treatment.
A total number of 75 treatment episodes were studied. In 21% pre-treatment circulating
t(14;18) positive cells were 0-10/75.000 cells with known t(14;18) positive lymphoma. In the
remainder the median number of pre-treatment circulating t(14;18) was 328 per 75.000 cells.
Numbers of pre-treatment circulating t(14;18) positive cells above the median correlated with
stage IV disease, bone marrow involvement, and overt leukaemic lymphoma. Treatment
episodes that cleared the circulation from t(14;18) positive cells with more than one log resulted
in a significantly longer progression-free survival than treatment episodes with less than one log
decline (26 versus 12 months respectively). After first-line treatment episodes, numbers of
circulating t(14;18) positive cells mainly declined irrespective of clinical response. For episodes
with 2nd or later lines of treatment, declining numbers of lymphoma cells correlated with a
clinical remission, whereas increasing numbers of lymphoma cells were associated with
clinically stable or progressive disease.
During the past decades, a discrepancy has appeared between the ever more sensitive diagnos-
tics in follicular lymphoma and a true improvement of the clinical outcome of these patients. In
the individual follicular lymphoma patient questions remain on the clinical significance of
quantitative monitoring of (residual) disease by real-time PCR of circulating t(14;18) positive
cells. Elucidating the exact mechanisms of the homing and spread of malignant lymphoma cells
is necessary before we can in fact rely on molecular diagnostics of the blood compartment
when evaluating the merits of (new) systemic therapies.
Samenvatting en discussie
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Folliculaire lymfomen vormen een aparte groep van maligne lymfomen met een karakteristiek
beloop van steeds recidiverende ziekte, welke uiteindelijk - na histologische transformatie - leidt
tot de dood van de patiënt, vaak jaren na het stellen van de diagnose. Behandeling van deze
patiënten blijft een dilemma. Een initieel afwachtend beleid bij de nog asymptomatische
patiënt beïnvloedt diens prognose niet ongunstig. Wanneer er eenmaal een indicatie tot
therapie is, zullen diverse behandelingsmodaliteiten en -schema's leiden tot een tijdelijke
respons. Helaas wordt hiermee in het algemeen slechts een verlenging van de progressie-vrije
overleving van de patiënt bereikt, en niet van de totale overleving. Een uitzondering hierop lijkt
te worden gevormd door intensivering van behandeling door middel van beenmerg-ablatieve
therapie, gevolgd door allogene stamceltransplantatie. Hierbij wordt niet alleen gebruik
gemaakt van de hooggedoseerde chemo- (en radio-) therapie, maar ook van het anti-tumor
effect uitgaande van de immuun-reactieve donor lymfocyten in het transplantaat, het zgn.
'graft-versus-lymphoma' effect. Gedurende de laatste decennia is de prognose van patiënten
met een folliculair lymfoom nog niet wezenlijk verbeterd, maar is de diagnostiek van dit
maligne lymfoom duidelijk sensitiever geworden. Door de introductie van de zgn. real-time
polymerase ketting reactie in de moleculaire diagnostiek kunnen namelijk cellen met de voor
het folliculaire lymfoom kenmerkende chromosomale translocatie t(14;18) zeer sensitief
gekwantificeerd worden. Het zou kunnen zijn dat deze moleculaire diagnostiek uiteindelijk
gebruikt gaat worden bij het bepalen van de optimale behandeling van de individuele patiënt.
In dit proefschrift worden studies over deze onderwerpen gepresenteerd.
In hoofdstuk 1 worden inzichten in de classificatie van de non-Hodgkin lymfomen besproken,
waarna nader ingegaan wordt op het folliculaire lymfoom. De pathologische anatomie, het
immunofenotype en de cytogenetica van dit lymfoom worden besproken, gevolgd door de
klinische kenmerken. Hierna wordt een overzicht van de mogelijke behandelingen gegeven,
inclusief de meer recente therapieën.
In hoofdstuk 2 worden de klinische resultaten gepresenteerd van allogene beenmerg
transplantatie (BMT) in het Universitair Medisch Centrum (U.M.C.) St Radboud bij patiënten
met een recidief indolent lymfoom met slechte prognose. Conditionering voor BMT bestond uit
cyclofosfamide en totale lichaamsbestraling, al dan niet met idarubicine. Beenmerg-
transplantaten werden verkregen van HLA-compatibele verwante donoren. Om het risico van
omgekeerde afstotingsziekte, de zgn. graft-versus-host disease (GVHD), te verkleinen werden
deze transplantaten gedepleteerd van T-lymfocyten door middel van counterflow centrifugatie.
Bovendien werd hiertoe na BMT ciclosporine A aan de patiënten toegediend. Vijftien patiënten
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met een mediane leeftijd van 47 jaar werden getransplanteerd. Rejectie van het transplantaat
vond niet plaats. Na een mediane observatieduur van  36 maanden (uitersten 9-78) waren 10
patiënten in leven en in complete remissie. Bij twee van hen recidiveerde de ziekte na BMT,
maar beiden bereikten opnieuw een complete remissie na infusie van lymfocyten van de
originele beenmergdonor. Vijf patiënten overleden aan resp. cardiomyopathie (n=1),
chronische GVHD (n=1) en infectie tijdens chronische GVHD (n=3).
In deze samenvatting van het proefschrift kan ik de resultaten actualiseren. Tot aan 1 april
2002 zijn 33 patiënten met een indolent non-Hodgkin lymfoom behandeld met een allogene
stamceltransplantatie in het U.M.C. St Radboud te Nijmegen. Na een mediane observatieduur
van 32 maanden (uitersten 1-138) zijn de progressie-vrije en totale overleving resp. 79% en
55% 5 jaar na transplantatie. Drie van de 32 patiënten (9%) hadden acute GVHD ≥ graad 3,
en 11 van de 26 (42%) uitgebreide chronische GVHD. Drie patiënten ontwikkelden een
recidief indolent lymfoom na de transplantatie, dat respondeerde op therapeutische donor
lymfocyten infusie (DLI). Profylactische DLI werd gegeven aan drie patiënten. Eén patiënt, die
stamcellen van een onverwante donor ontving na anti-thymocyten globuline bevattende
conditionering, ontwikkelde een post-transplantatie lymfoproliferatieve aandoening.
Een allogene T-cel gedepleteerde stamceltransplantatie, weliswaar geassocieerd met
complicaties, is een effectieve behandeling voor patiënten met een recidief indolent lymfoom
met slechte prognose.
Omdat het folliculaire lymfoom een indolent ziektebeloop kent met een mediane overleving
van patiënten van 7-10 jaar, zal het tenminste jaren, zo niet decennia duren vooraleer een
overlevingsvoordeel werkelijk toegeschreven kan worden aan een nieuwe therapie. Monitoring
van ziekte-activiteit met behulp van moleculaire diagnostiek zou een rol kunnen spelen bij het
bepalen van de effectiviteit van een behandeling op een eerder tijdstip dan dat dit op basis van
klinische diagnostiek zou kunnen, zoals bijv. door het vaststellen van de overleving na therapie.
Circulerende lymfoomcellen kunnen nu door de kwalitatieve en recentelijk ook kwantitatieve
polymerase ketting reactie (PCR) bepaald worden, waarbij gebruik gemaakt wordt van de
chromosomale translocatie t(14;18), kenmerkend voor het folliculaire lymfoom.
Wij ontwikkelden een real-time kwantitatieve t(14;18) PCR, zoals beschreven in
hoofdstuk 3. Vergeleken met conventionele PCR heeft de real-time PCR een lage fout-
positiviteit omdat gebruik gemaakt wordt van een gesloten systeem voor amplificatie en
detectie. Positiviteit wordt bepaald in de exponentiële fase van de reactie op de zgn. drempel
cyclus, welke proportioneel is aan het initiële aantal t(14;18) positieve cellen. Het t(14;18) PCR
signaal, dat een maat is voor lymfoomcellen, wordt genormaliseerd voor dat van β-actine, op
zijn beurt een maat voor de totale hoeveelheid DNA. Voor kwantificering wordt het
genormaliseerde t(14;18) signaal gerelateerd aan een calibrator.
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In hoofdstuk 4 wordt een nieuwe methode gepresenteerd om een gebruikelijk probleem in de
real-time kwantitatieve PCR op te lossen, te weten de verschillen in amplificatie efficiëntie
tussen DNA monsters. In het algemeen zijn bij het folliculair lymfoom de amplificatie
efficiënties van de t(14;18) en albumine PCR hoger in bloedmonsters dan in lymfkliermonsters;
in één monster tonen beide reacties echter gelijke efficiënties. Bij monsters van patiënten met
een amplificatie efficiëntie die lager is dan die van de calibrator, kan ziekte-activiteit onderschat
worden, vooral wanneer zeer kleine aantallen t(14;18) positieve cellen aanwezig zijn. Om
verschillen tussen de amplificatie efficiëntie van patiënten monsters en van de calibrator te
compenseren, worden twee referentie reacties gebruikt, die specifiek zijn voor de β-actine en
albumine huishoudgenen. Op deze manier kan men patiënten monsters herkennen die in grote
mate besmet zijn met PCR-remmende factoren, die de verschillende amplificatie reacties
wisselend beïnvloeden, hetgeen een nauwkeurige kwantificering van ziekte-activiteit
onmogelijk maakt.
Sinds de introductie van de real-time PCR in de moleculaire diagnostiek kunnen nu cellen met
de chromosomale translocatie t(14;18) bij het folliculaire lymfoom gekwantificeerd worden met
een gevoeligheid van detectie van 1 maligne cel uit 150.000 normale cellen. In eerste instantie
zou men kunnen veronderstellen dat het aantal circulerende lymfoomcellen correleert met de
ziekte-activiteit. Zo zou men dan een afname van circulerende t(14;18) positieve cellen
verwachten bij patiënten die responderen op behandeling, en een toename bij een later
recidief.
Zoals beschreven in hoofdstuk 5, kon er inderdaad bij een patiënte met een recidief
folliculair lymfoom na allogene BMT een graft-versus-lymphoma effect van donor lymfocyten
infusie bevestigd worden door real-time kwantitatieve PCR analyse van t(14;18). Deze 48-
jarige vrouw met een recidief indolent folliculair lymfoom werd behandeld met beenmerg-
ablatieve therapie, gevolgd door infusie van T-cel gedepleteerd beenmerg van haar HLA-
identieke zus. Zij ontwikkelde geen omgekeerde afstotingsziekte. Tweeëntwintig maanden later
werd een recidief vastgesteld van een onveranderd lage maligniteitsgraad in de initieel
aangedane lymfklieren en in het beenmerg. Behandeling met alleen lymfocyten van de
originele beenmergdonor resulteerde geleidelijk in een complete remissie, met een beenmerg
zonder tekenen van maligne lymfoom. Voorbijgaande klachten van een droge mond, waarvan
werd aangenomen dat deze op een beperkte chronische omgekeerde afstotingsziekte berustten,
werden niet behandeld.
In de loop der tijd werden bij deze patiënte lymfoomcellen in het perifere bloed en
beenmerg gemonitord door middel van real-time PCR analyse t(14;18) positieve cellen. Na
BMT persisteerden lymfoomcellen in bloed en beenmerg, terwijl patiënte klinisch in een
120
Samenvatting en discussie
complete remissie verkeerde. Het aantal lymfoomcellen nam duidelijk toe voor de klinische
presentatie van het recidief en nam vervolgens af tot niet meer detecteerbare waarden na DLI.
De bevindingen bij deze patiënte laten zien dat real-time kwantitatieve PCR analyse van
t(14;18) een veelbelovende nieuwe techniek is om de moleculaire ziekte status te bepalen bij
het folliculaire lymfoom. Daarom zou deze bepaling gebruikt kunnen worden om de effectiviteit
van behandeling vast te stellen en ook de prognose van de patiënt.
Hoofdstuk 6 geeft een overzicht van intensieve therapie bij patiënten met een recidief
indolent lymfoom, bestaande uit beenmerg-ablatieve therapie gevolgd door autologe of
allogene stamceltransplantatie (SCT). Omdat diverse conventionele behandelingen hebben
geresulteerd in een verbeterde progressie-vrije, maar niet totale overleving van patiënten, wordt
intensivering van behandeling door middel van SCT nu steeds frequenter toegepast. Bij beide
vormen van transplantatie maakt men gebruik van het anti-tumor effect van de hoge dosis
conditionering, waarbij bij de allogene transplantatie ook het additionele graft-versus-lym-
phoma effect benut wordt. Daarom lijkt een allogene SCT een veelbelovende en potentieel
curatieve therapie voor een geselecteerde groep van patiënten met een indolent lymfoom,
ondanks complicaties als omgekeerde afstotingsziekte en de met de behandeling
samenhangende sterfte. Een allogene SCT vroeg in het beloop van een indolent lymfoom, te
weten bij het eerste recidief, dient serieus overwogen te worden bij een patiënt die een HLA-
compatibele donor heeft.
Bij een recidief haematologische ziekte na allogene SCT kan nog altijd een remissie bereikt
worden door de balans tussen patiënt en donor immuun-reactieve cellen te doen doorslaan ten
gunste van de donor. Dit is enerzijds mogelijk door vermindering van de immuunsuppressieve
medicatie aan de patiënt, en anderzijds door infusie van lymfocyten, die afkomstig zijn van de
originele stamceldonor.
In hoofdstuk 7 wordt het graft-versus-lymphoma effect van donor lymfocyten infusies
beschreven aan zeven patiënten met een recidief indolent lymfoom na allogene SCT. In de
beschikbare beenmerg- en bloedmonsters werden lymfoomcellen gemonitord door real-time
PCR van t(14;18) positieve cellen bij het folliculair lymfoom en door immunofenotypering bij
het kleincellig lymfocytair lymfoom. Voorafgaand aan DLI was het vanwege klinisch
bedreigende recidieven noodzakelijk drie patiënten te behandelen met chemo- en/of
radiotherapie en één patiënt met rituximab. Evalueerbare responsen op deze pre-DLI therapie
waren stabiele ziekte (n=1) en partiële remissie (n=2). De gerecidiveerde lymfomen
respondeerden geleidelijk op DLI tot aan een complete remissie (n=4) en partiële remissie
(n=3). Bij drie patiënten beschikten wij over bloed- en/of beenmergmonsters die op
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opeenvolgende tijdstippen waren afgenomen voor en na DLI. Bij alle drie kon de klinische
respons bevestigd worden door moleculaire resp. immunofenotypische analyse van
lymfoomcellen. Vijf patiënten zijn thans nog in leven en maken het goed; hun respons op DLI
duurt mediaan 30 maanden (uitersten 5-70). Twee en 17 maanden na DLI overleden twee
patiënten aan de gevolgen van respectievelijk een Aspergillus fumigatus pneumonie en
leverfalen e.c.i.. Na DLI trad acute omgekeerde afstotingsziekte op bij drie patiënten,
geclassificeerd als graad 2; alleen een beperkte chronische omgekeerde afstotingsziekte werd
waargenomen bij vijf patiënten. DLI is een effectieve behandeling voor recidief indolente
lymfomen na SCT.
Nadat wij een goede correlatie hadden aangetoond tussen de klinische en moleculaire
bevindingen bij met DLI behandelde patiënten, verwachtten wij dat het aantal circulerende
t(14;18) positieve cellen ook overeen zou komen met de klinische ziekte-activiteit van het
folliculaire lymfoom bij andere therapieën. Als dit zo zou zijn, zou moleculaire diagnostiek
gebruikt kunnen worden om de optimale behandeling vast te stellen van de individuele patiënt
met een folliculair lymfoom. Zo zou men bijvoorbeeld bij een patiënt bij wie na een
behandeling op moleculair niveau ziekte aantoonbaar blijft, een potentieel curatieve therapie
als allogene SCT kunnen overwegen op een vroeger tijdstip dan bij het pas klinisch duidelijk
worden van het recidief.
In hoofdstuk 8 wordt de klinische betekenis beschreven van kwantificering van
circulerende t(14;18) positieve cellen door middel van real-time PCR in de eerste lijns
behandeling van het folliculair lymfoom. In een prospectieve studie werd t(14;18) gemonitord
in het perifere bloed van 34 patiënten met een folliculair lymfoom, die uniform behandeld
werden met standaard chemotherapie in combinatie met interferon-alfa 2b. Bij presentatie van
de ziekte werden mediaan 262 t(14;18) positieve cellen per 75.000 normale cellen (uitersten 1-
75.000) gevonden. Dit aantal is duidelijk groter dan het aantal dat wij met real-time PCR
aantoonden in bloed van 15 van 102 onderzochte gezonde personen, nl. 1-10 t(14;18)
positieve cellen per 75.000 cellen. Bij patiënten van wie het aantal circulerende t(14;18) groter
was dan de mediane waarde, kwam stadium IV ziekte significant vaker voor dan bij hen met
kleinere aantallen. Daarentegen was bulky ziekte significant frequenter in de groep met
aantallen circulerende t(14;18) kleiner dan de mediaan dan bij die met grotere aantallen. Bij 22
van de 28 patiënten daalde het aantal circulerende t(14;18) positieve cellen na therapie tot niet
meer te detecteren of lage aantallen; dit was ook het geval bij vier patiënten bij wie
behandeling klinisch had gefaald. Bij de overige responderende patiënten persisteerden
circulerende lymfoomcellen na therapie.
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De kwantitatieve gegevens over circulerende t(14;18) positieve cellen, zoals beschreven in
hoofdstuk 8, zetten vraagtekens bij de klinische betekenis van moleculaire monitoring van het
bloed bij eerste lijns, niet curatieve behandeling van het folliculaire lymfoom. Daarentegen
wordt later in het beloop van de ziekte, nl. ten tijde van donor lymfocyten infusies, een
uitstekende correlatie tussen klinische en moleculaire bevindingen gevonden. Dit suggereert
een verschil in het (opnieuw) verschijnen van t(14;18) positieve cellen in het perifere bloed
tussen patiënten in een vroege of juist latere fase van het folliculair lymfoom.
Hoofdstuk 9 beschrijft de dynamica van circulerende t(14;18) positieve cellen tijdens
eerste lijns en volgende lijnen van behandeling bij het folliculaire lymfoom. Bij 56 patiënten,
die een eerste of volgende lijn van conventionele therapie kregen, werden ziekte parameters en
respons op behandeling vergeleken met real-time kwantitatieve PCR gegevens over
circulerende t(14;18) positieve cellen. In totaal werden 75 episoden van behandeling
bestudeerd. Bij 21% hiervan was het aantal circulerende t(14;18) positieve cellen voor therapie
0-10 per 75.000 cellen bij een bekend t(14;18) positief lymfoom. Bij de overige was het aantal
circulerende t(14;18) voor therapie mediaan 328 per 75.000 cellen. Aantallen van pre-therapie
circulerende t(14;18) positieve cellen groter dan de mediaan correleerden aan stadium IV
ziekte, beenmerg invasie door lymfoom en duidelijk leukemisch lymfoom. Episoden van
behandeling waarbij de circulatie van t(14;18) positieve cellen met meer dan één log geklaard
werd, resulteerden in een significant langere progressie-vrije overleving dan episoden waarbij
een minder dan één log afname (26 versus 12 maanden resp.). Na eerste lijns
behandelingsepisoden zagen we voornamelijk een daling in aantallen circulerende t(14;18)
positieve cellen; dit hing niet samen met de klinische respons. Daarentegen correleerde na
tweede of latere lijns therapie een afname in aantal circulerende lymfoomcellen met een
klinische remissie, terwijl een toename geassocieerd was aan klinisch stabiele of progressieve
ziekte.
Gedurende de laatste decennia is er een discrepantie ontstaan tussen de alsmaar sensitievere
diagnostiek van het folliculaire lymfoom en het uitblijven van een daadwerkelijke verbetering
van het klinisch resultaat van de behandeling van deze patiënten. Bij de individuele patiënt met
een folliculair lymfoom blijven er vragen bestaan over de klinische betekenis van kwantitatieve
monitoring van (residuale) ziekte door middel van real-time PCR van circulerende t(14;18)
positieve cellen. Pas wanneer opgehelderd is waarom maligne lymfoomcellen in lymfklieren
blijven of juist vanuit deze lymfklieren dissemineren in de bloedbaan, kan men vertrouwen op
de moleculaire diagnostiek van het bloed bij de evaluatie van (nieuwe) systemische therapieën.
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Dankwoord
Dit proefschrift is voor een belangrijk deel tot stand gekomen tijdens mijn werkzaamheden als
(arts-assistent geneeskunde in opleiding tot) internist bij de afdeling bloedziekten van het
Universitair Medisch Centrum (U.M.C.) St Radboud te Nijmegen. Dat dit mogelijk werd, heb ik
te danken aan velen.
Allereerst wil ik de internisten van het St. Joseph Ziekenhuis te Veldhoven noemen. Beste
collegae, alleen door jullie grondige opleiding kon de basis gelegd worden voor mijn
werkzaamheden als internist en voor de combinatie hiervan met wetenschappelijk onderzoek.
Mijn dank hiervoor aan o.a. dr. P.G.G. Gerlag ('wat is de hydratie toestand van de patiënt?'), dr.
F.E. van Dam ('Caroline, een niertransplantatie, pneumococcen sepsis én maagzweer tegelijk
kan niet!') en dr. J.J. Keuning ('het kan ook een lymfoom zijn').
Aangekomen in het U.M.C. St Radboud was al snel het contact met de afdeling
bloedziekten gelegd. Prof. dr. T.J.M. de Witte, beste Theo, ik dank je voor je vertrouwen in mij
dat ik een gepromoveerde haematoloog kon worden en voor je steun op momenten dat ik dit
wat minder zag zitten. Jouw optimisme deed me goed. Dr. J.M.M. Raemaekers, beste John, op
de verpleegafdeling bloedziekten maakte ik voor het eerst kennis met jou en je
indrukwekkende klinische blik; veel heb ik van je geleerd. Later deden wij samen aan
wetenschap, hetgeen niet altijd even gladjes verliep. Dat dit proefschrift nu hier voor ons ligt,
moet ons beiden toch tot blijdschap stemmen.
Dr. E.J.B.M. Mensink en dr. J.P.P. Meijerink, beste Ewald en Jules, jullie moesten mij als
eenvoudig internist voorlichten over ingewikkelde zaken als de polymerase ketting reactie, de
dubbel gelabelde fluorogene MBR interne probe met 5'-(TET)-CAC AGA CCC ACC CAG
AGC CC-(TAMRA)-p3', epjes, en nog veel meer. Mijn dank hiervoor. Nu nog heb ik ontzag
voor alleen al het in Word kunnen invoeren van alle formules in hoofdstuk 4, Jules. Direct
hierna wil ik E.L.R.T.M. Tönnissen noemen, beste Evelyn, door jou begreep ik de polymerase
ketting reactie pas echt. Dank hiervoor, en vooral ook voor al je t(14;18) bepalingen.
Alle nog niet genoemde stafleden van de afdeling bloedziekten wil ik bedanken voor hun
opleiding en steun, hierbij ook mijn dank aan de tijdelijke stafleden. Niet vergeten wil ik drs.
E.A. Roovers, beste Lian, van jou leerde ik hoe een computer werkt en hoe deze goed in te
zetten bij wetenschappelijk onderzoek, dank je wel.
Een belangrijke plaats in mijn wording tot internist-haematoloog heeft de verpleging van
zowel afdeling als polikliniek bloedziekten ingenomen. Allen (te veel om op te noemen), ik heb
bewondering voor jullie en ik ben van mening dat haematologen niet veel zijn zonder jullie. De
haematologische patiënt mag zich gelukkig prijzen met steun van verpleegkundigen als jullie!
Bedankt voor jullie luisterend oor, jullie lach en al dat lekkers in de keuken. Secretaresses van
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afdeling, polikliniek en dagverpleging wil ik ook hierbij scharen.
Veel dank ben ik verschuldigd aan de patiënten, die eigenlijk altijd hun bloed (en
beenmerg) af wilden staan voor mijn onderzoek. Ik hoop van harte dat wetenschappelijk
onderzoek, waaraan mijn bijdrage slechts bescheiden is, tot een verbetering van Uw leven en
overleving zal leiden! Alle in maar vooral ook buiten het U.M.C. St Radboud werkzame
internisten, haematologen en oncologen wil ik danken voor de inclusie van de vele patiënten
in mijn studies en voor het zorg dragen voor het tijdig afnemen van al het bcl-2 bloed in de
zgn. 'Mandigers-buizen'. Ook mijn dank aan Robert Alferink, zonder wie deze bloedmonsters
ons laboratorium nooit in bevroren toestand bereikt zouden hebben.
Nog enkelen uit het U.M.C. St Radboud wil ik hier noemen. Allereerst dr. M.J.J.T.
Bogman, beste José, je leerde mij hoe belangrijk overleg tussen patholoog en clinicus is. Jouw
nuchtere kijk op een leven als een academische dan wel perifere dokter is erg waardevol voor
mij geweest. Sorry voor mijn stelling over de P.A. classificatie. Ir. J.B.M. Boezeman, beste Jan,
bedankt dat ik je op al die zondagmiddagen kon bellen wanneer ik mijn i-mac even niet
begreep. Tot slot: Gaby, Mariëtte en Corrie van de aferese afdeling, het was fijn dat ik, destijds
nog als zwerfster door het ziekenhuis, welkom was op jullie kamer.
Op deze plaats wil ik ook mijn collega-internisten in het Canisius-Wilhelmina Ziekenhuis
(C.W.Z.) danken voor hun vertrouwen dat ik mijn promotie onderzoek zou afronden. Dat dit
nog bijna drie jaar na aankomst in het C.W.Z. zou duren, voorzag ik niet, jullie daarentegen
misschien wel. Tijdens een dubbelleven als academische en perifere dokter is het goed samen
te werken met jullie, bedankt!
Mijn dank gaat uit naar dr. E. Tetteroo. Beste Eric, je bood zomaar aan om van mijn Word,
Excel en PowerPoint bestanden dit boekje te maken. Het ziet er geweldig uit!
Na alle boven genoemden, wil ik hier een bijzonder woord van dank zeggen aan mijn lieve
ouders, zonder wie ik nooit zover zou zijn gekomen. Ook noem ik hier mijn paranimfen.
Allereerst mijn broer, ir. H.F.J. Mandigers, lieve Herman, bedankt dat je mij ondanks je eigen
beslommeringen bij wilt staan. Ik vertrouw erop dat je elke vraag (bedrijfs)kundig zult kunnen
pareren. Vervolgens mijn dank aan drs. M. Oosterveld. Beste Margriet, als verstandige
Noorderling sta jij met beide benen op de grond, ondanks een stukje onwillig kraakbeen. Jouw
steun, collegialiteit en vriendschap voor, tijdens en ook na mijn promotie zal ik niet vergeten.
Succes met je eigen boekje, Easterfield.
Tot slot wil ik op deze plaats mijn aanstaande echtgenoot Mike Korst noemen. Lieve Mike,
zonder je wijsheid en je heldere visie op zaken die mij bezighouden, was dit proefschrift nooit
tot stand gekomen. Dank je wel! Eindelijk heb ik meer tijd voor jou...
126
Samenvatting en discussie
Samenvatting en discussie
127
Curriculum vitae
De auteur van dit proefschrift werd geboren op 31 januari 1965 te Mierlo. Zij behaalde in 1983
het eindexamen Gymnasium β aan het Augustinianum te Eindhoven. In datzelfde jaar begon
zij met de studie geneeskunde aan de Katholieke Universiteit Nijmegen. Na het doctoraal
examen in 1987 werd hier in 1990 het artsexamen behaald. Na twee jaar arts-assistent interne
geneeskunde niet in opleiding te zijn geweest, kon in 1992 de opleiding tot internist
aangevangen worden. In achtereenvolgens het St. Joseph Ziekenhuis te Veldhoven (opleider
dr. P.G.G. Gerlag) en het Academisch Ziekenhuis Nijmegen St. Radboud (opleider prof. dr. A.
van ‘t Laar en later prof. dr. J.W.M. van der Meer) werd zij geschoold tot internist. In augustus
1997 vond registratie als internist plaats. Vanaf augustus 1996 was zij in het kader van het
aandachtsgebied haematologie werkzaam op de afdeling bloedziekten van het Academisch
Ziekenhuis Nijmegen St. Radboud (opleider prof. dr. T.J.M. de Witte). Hier werd het in dit
proefschrift beschreven onderzoek aangevangen. In maart 1999 werd zij geregistreerd als
haematoloog. Sinds november 1999 is zij gevestigd als internist in het Canisius-Wilhelmina
Ziekenhuis te Nijmegen.
Stellingen behorende bij het proefschrift getiteld Treatment of patients with follicular
lymphoma, a role for molecular diagnostics?
1. Aantrekkelijk maar onjuist is het om bij patiënten met een folliculair lymfoom altijd
een rechtlijnig verband aan te nemen tussen het aantal circulerende t(14;18)
positieve lymfocyten en de klinische ziekte activiteit (dit proefschrift).
2. Door middel van real-time PCR monitoring van t(14;18) positieve lymfocyten
kunnen in het bloed van een patiënt met een folliculair lymfoom verschillen in
aantallen lymfoomcellen in de loop der tijd aangetoond worden, die met de
kwalitatieve PCR gemist zouden kunnen zijn (dit proefschrift).
3. Toename van kennis bij een patiënt met een folliculair lymfoom, zoals zijn aantal
circulerende t(14;18) positieve lymfocyten, is nog niet hetzelfde als toename in
begrip van zijn ziekte.
4. Het is nog te vroeg om de resultaten van kwantitatieve monitoring van circulerende
t(14;18) positieve lymfocyten te laten meewegen in de beslissing over behandeling
van de patiënt met een folliculair lymfoom (dit proefschrift).
5. De voor de gewone dokter onnavolgbare groei in de genetische kennis over
bloedziekten belooft niet veel goeds voor diens hoop op een klinisch-pathologische
classificatie van bloedziekten die decennia lang stand zal houden.
6. Vriendelijkheid kost echt niets en zou een belangrijker rol kunnen spelen in de
communicatie tussen arts en patiënt, maar ook tussen artsen onderling.
7. In het hockey verhoogt de backhandslag onnodig het risico op lichamelijk letsel en
dient daarom verboden te worden.
8. Het is verbazingwekkend hoeveel niet al te belangrijke informatie schijnt te moeten
worden doorgebeld sinds de invoering van de mobiele telefonie.
9. Ook palliatieve zorg doet goed.
10. Nu in de nieuwe spelling linkerarm één woord is geworden en ruggenmerg op één
rug betrekking heeft, is er niet één die altijd foutloos schrijft.
11. Als bespreking 'meeting' wordt en praatje 'presentatie', dan wordt het tijd om minder
belangrijk te doen.
12. Het is een kunst om met te weinig tijd, toch tijd te nemen voor de patiënt.
Caroline M.P.W. Mandigers, 10 september 2002
